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Report of The Provincial Advisory Committee on 
New Predictive Genetic Technologies
Executive Summary
During the past decade, science has made enormous advances in understanding the
human genome. Sophisticated technologies have permitted human gene mapping on
an unprecedented level. The increasing ability to test for genetic predisposition to
disease has resulted in optimism that genetic predictive testing will help improve
treatments and health care delivery. An understanding of the genetic basis of disease
is expected to help everyone better understand disease processes.
Public polls show that people in Ontario are interested in learning more about
the new genetic sciences and what they will mean to them. Before embracing these
new technologies, governments need to carefully examine their value and their
consequences for patient outcomes, legal systems and society.
The Committee
In April 2000, the Ministry of Health and Long-Term Care (MOHLTC) established a
Provincial Advisory Committee on New Predictive Genetic Technologies to help
Ontario navigate the new frontier of human genetic medicine and science. 
The mandate of the Advisory Committee was to develop a policy framework for
introducing new genetic predictive testing and services into Ontario’s health care
system. This framework would help ensure that the provincial health system
promotes wellness and improves health outcomes in advance of the appearance of
disease.
The Committee would also develop guidelines, principles, broad criteria and
advice to guide decisions on how new genetic services should be incorporated into
the province’s health care system. See Appendix A for Terms of Reference for the
Committee.
The multidisciplinary Committee was made up of:
n geneticists, 
n a genetic counsellor, 
n family physicians, 
n genetic researchers, 
n laboratory directors, 
n academics in law, ethics and medicine, educators, 
n a clinical epidemiologist,
n an expert in psychosocial issues, and 
n representatives from the Canadian Cancer Society, the Heart and Stroke
Foundation, the Huntington Society of Canada, the Ontario Association of
Medical Laboratories, the Ontario College of Family Physicians, the Ontario
Hospital Association, and the Ministry of Health and Long-Term Care. 
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The work of the Committee was divided among six areas:
n education,
n evaluation,
n clinical practice,
n psychosocial issues,
n laboratory practice, and
n legal and ethical issues
The sub-committees drew on a broad base of provincial expertise in each of these
areas. Membership of the Provincial Advisory Committee and its sub-committees
appear in Appendix B. 
The Report
This report will help MOHLTC understand recent advances in genetic science. The
report also examines the current state of genetic services in Ontario, and anticipates
numerous impacts that genetic medicine and technology will have on patients, the
physician-patient relationship, the health care system, and society. 
Although the effects of genetic science on clinical practice, health services and
individuals are still to be seen, the rapid increase in genetic technology requires
responsive strategies and an objective assessment of the immediate and future scope
of these advances. 
The report directs its recommendations to the provincial and federal
governments and to non-governmental bodies who can ensure that people in
Ontario benefit from genetic science.
Impacts of New Genetic Technology
On Health Systems
Differences in the reliability, accuracy and predictive power of new genetic
technologies, as well as clinical and psychosocial impacts, mean that each new
technology must be evaluated for its usefulness and impact within a public health
system. 
The complex nature of each test procedure requires strict laboratory protocols to
ensure the test results are accurate, meaningful and can be clearly communicated
from physician to patient. 
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On Clinical Practice
Genetic tests vary significantly in the degree of certainty of developing disease, the
risk and reliability associated with the test, the type of treatment required, and the
complexity of their management. As the number and type of genetic tests increases,
family physicians will encounter increasing indications for these tests and then will
need to interpret the results. 
Increasing genetic tests will also increase the workload of medical geneticists,
other medical specialists and genetic counsellors. New approaches to clinical
practice will need to be developed and in order to be fully effective, physicians will
need to acquire new knowledge and integrate skills from different fields.
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John, James and Paul 
John’s older brother, James (28), is recently
diagnosed with colon cancer. Their father died
of colon cancer at the age of 39. John (23),
concerned about his own risk, gets referred to a
genetics clinic.
The genetics clinic counsellor tells John his
family would be eligible for testing but they need
James’ medical records to verify the diagnosis. If
testing were to be done, they would have to start
with James. John is reluctant to ask his brother
who has recently been through surgery and is
undergoing chemotherapy. The counsellor tells
John he is at high risk based on his family
history and so he should start having annual
colonoscopies. She refers him to a
gastroenterologist.
Four years later, James is doing well. John
and his new wife want to start a family so John
talks to James about testing. James agrees to be
tested and is found to have a mutation in the
MSH2 gene, which is consistent with the family
history of colon cancer. John is tested and does
not have the mutation. His gastroenterologist tells
him to stop his current level of surveillance and
that he needs only to follow normal precautions. 
Their younger brother, Paul, learns of James’
result and requests testing. Prior to testing, he has
always been healthy, had no surveillance and hasn’t
thought much about either colon cancer or his
health in general. He is counselled about the
potential medical and psychosocial effects of the
testing, seems to understand and is eager to
proceed. 
Testing shows he carries the same mutation as
James. He is told this mutation is associated with
an 80% chance of developing colon cancer in his
lifetime (as compared to the population risk of 6%).
He is referred to a gastroenterologist for
colonoscopy. Although the result is normal, he
becomes extremely anxious about developing
cancer and requests a second opinion. The second
normal colonoscopy doesn’t seem to relieve his
anxiety; his family also reports that he spends
hours searching the Internet for possible ways to
prevent colon cancer. 
His family doctor refers him to a psychiatrist
who treats him for about a year. Paul’s anxiety
slowly abates although it is heightened for the two
weeks before each colonoscopy appointment. 
On the Patient
The probabilities and risks of genetic information are difficult concepts to
understand and to base decisions on. Careful attention must be paid not only to the
clinical information provided to the patient but also to the psychosocial effects
which the testing may have on the individual and their families. 
Unlike other forms of medical diagnosis, genetic predictive testing spans
generations. Testing individuals also tests other family members, including offspring
and their offspring. The test for Huntington Disease, for example, is predictive for
the individual tested and also for future generations. 
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David 
32-year-old David’s father, John, has recently been
diagnosed with hemochromatosis, a genetic disorder
where iron accumulation in body tissues results in
multiple problems including cirrhosis of the liver,
diabetes, impotence, skin bronzing and heart failure.
This disorder is easily treated by regularly bleeding
the patient to remove iron from the body. David’s
father was diagnosed early enough to reverse the
effects of the disease with this treatment. 
John’s genetic testing revealed he carries two
copies of the C282Y mutation in the
hemochromatosis gene. This mutation, when
present in two copies, is known to be associated
with the disease. David asks his doctor if he,
David, should start treatment which in this case
consists of removing blood on a regular basis.
David’s doctor suggests that he have DNA
testing before undergoing treatment. A blood test
indicates that David has one copy of the C282Y
gene and one copy of the normal form of the gene.
Unfortunately, the laboratory erroneously interprets
this result as predisposing David to
hemochromatosis. David’s doctor starts him on
monthly blood letting. 
Six months later, David has become anemic.
The doctor, puzzled by this result, seeks the advice
of a hematologist who explains that David’s DNA
result is, in fact, not consistent with a
predisposition to hemochromatosis; he is merely a
carrier like 10% of the Caucasian population.
Therefore, David’s anemia is to be expected, given
the amount of blood he has been giving over the
past six months. 
The hematologist also reminds David’s doctor
that a predisposition doesn’t mean that a person has
the disease, so further testing for signs of the
disease should be done before treatment is begun.
Karen 
Karen, a 35-year-old woman, has read about a new
gene test for breast cancer. She has no family history
of breast cancer but her best friend recently died
of the disease at the age of 36 so she is worried.
She visits her family doctor and demands the test. 
The doctor refers Karen to a genetic centre
counsellor who explains the complexity of testing
and the implications of both positive and negative
results. The counsellor tells Karen that based on
family history, she is not eligible for testing.
Karen is not totally satisfied with this answer
and tells her family doctor that she has heard that,
if she is willing to pay, she can send her blood out
of province for testing. The family doctor agrees to
facilitate this for her but advises against it. A month
later, the testing laboratory result says Karen has a
change in her gene that has never been seen before,
so its significance is unknown. 
The family doctor suggests that she return to the
genetic centre where a geneticist tells her that the
gene is not perfectly understood and that previously
undescribed changes are frequently found. These
changes are impossible to interpret and therefore,
she cannot tell Karen whether her risk is increased
or not. Karen gets the same answer from the genetic
counsellor at the testing laboratory. She tells the
counsellor that she regrets having the test.
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Helen
Helen is a 27-year-old married lawyer whose 
60-year-old mother is in the last stages of
Huntington’s Disease (HD). Helen understands
she has a 50% chance of having inherited it and
that there is no specific treatment or cure. She
tells a geneticist that she wants to have testing so
she and her husband can make reproductive
choices. Secondarily, she has been offered a job
with less benefits than she receives now and feels
that the information about her HD status will
help her plan her career. 
Testing shows that Helen carries the HD gene
but neurological assessment confirms she has no
symptoms or signs of the disease. She is somewhat
depressed by the DNA result but is encouraged by
her normal neurological examination.
Helen returns to the clinic for a follow-up
appointment a year later with her husband and
newborn son. The couple proceeded to have a child
having decided against prenatal testing since they
hoped that advancing research would have
something to offer Helen and by extension, their
children if they inherit the gene. 
Helen tells the geneticist that she is staying at
her present job because she has a group life
insurance policy plus a good pension plan and she
doesn’t want to lose these benefits even though she
may earn more in the private sector. She also feels
that staying in her current job will allow her more
flexibility to spend time with her family. 
Although saddened by the news that she carries
the HD gene, Helen believes the knowledge has
allowed her to plan her life in a very positive way
and she is happy.
On the Public
Advances in biomedical science and new technologies offer an array of new health
and reproductive choices. To make informed choices, the public needs reliable
information about what is medically necessary and ethically appropriate. 
Challenges of New Genetic Technology
Because risk is often determined by complex interactions with other genes and with
environmental factors, interpreting the risk or probability of conditions through
genetic testing will require a unique educational strategy. 
Weighing the costs of providing a test and all the consequent lifestyle changes,
surveillance programs, potential psychological, family, ethical and legal impacts
against reliance on other sources of information and traditional clinical practices for
dealing with disease is a concern. 
There is a need to guard against controlling disease through the new genetic
technologies at the expense of other, known approaches to disease. Other
approaches to disease control will need to be considered, including lifestyle changes
that apply to the entire population, irrespective of genetic predisposition.
New testing technologies where one small blood or tissue sample can be tested
simultaneously for many different disorders will open up new possibilities not
previously contemplated.
Predictive genetic testing opens legal and ethical dilemmas that require guidance
and decisions based on shared social values in the context of a public debate. It also
raises issues that go beyond the provincial realm to areas of federal and international
regulation. 
Overview of the Recommendations
The recommendations of the Advisory Committee appear in section 3 of this report.
A Permanent Advisory Committee on Genetics
The initial recommendation is that Ontario establish a permanent and more broadly
mandated Advisory Committee on Genetics:
n to evaluate new genetic tests for service delivery, 
n to determine resource needs and health care service approaches as genetic issues
evolve, 
n to facilitate the implementation of new genetic tests, and 
n to provide advice on educational, legal, and ethical issues relating to genetic testing. 
The Need for Evaluation
The recommendations reiterate the importance of developing an evaluation process
that builds on the template presented in this report. Before becoming insured
services, all new tests should be evaluated for:
n technical accuracy, 
n clinical effectiveness, 
n usefulness to tested individuals, 
n adverse and additional effects, 
n expansion potential and cost, 
n ethical/legal implications, and 
n resource implications. 
6 Genetic Services in Ontario: Mapping the Future
Genetic Service Issues
Since genetic testing often produces complex results, testing must be part of broader
integrated multidisciplinary genetic services that incorporate genetic assessment and
counselling, quality testing, psychosocial support and follow-up services, including
surveillance, prevention and treatment. Every effort should be made to integrate
genetic service into current health care.
Because of the potential growth in the number and volume of genetic tests and
their accompanying costs and consequences over the coming decades, the
Committee has also made recommendations to increase recruitment and training
capacity for genetic service health care providers. Each aspect of genetic services
should have quality management guidelines in place. 
Ethical and Legal Issues
Ethical and legal issues permeate every phase of predictive genetic testing.
Recommendations emphasize the need:
n to ensure privacy and confidentiality and protect patients from discrimination
and stigmatization, 
n for fully informed consent for genetic testing, 
n to ensure quality management in laboratory testing, and 
n for governments and regulatory bodies to examine and take steps in the areas of
patents, commercial use and direct marketing of genetic testing. 
Educational Program
The Advisory Committee recommended developing and promoting a genetics
educational program for everyone in Ontario including health professionals and
decision-makers to meet public and professional needs. They also recommended
developing a specific education program for each new predictive genetic test
approved as an insured service.
Until recently, much of the practice of genetics involved diagnosing rare
inherited disorders, estimating risk for family members, and providing prenatal
diagnosis. There was little need for most health care providers to have any more
than a rudimentary knowledge of genetics. Now, there is an urgent need for the
Ministries of Education and of Colleges and Universities to review the curricula of
secondary and post-secondary schools and incorporate core genetic issues. 
Moving Forward
Governments, citizens and scientists are attempting to understand the benefits and
the limitations of genetics. This report attempts to assist Ontario in that endeavour
with confident caution. The monitoring of developments in genetics and the
resulting genetic clinical practice is an ongoing task for all governments.
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Section 1: Overview 
Science’s success in mapping the human genome is an event of considerable
magnitude. It is important, not just for its technological achievement, but for its
potential in helping to alleviate human suffering and improve the quality and
longevity of people’s lives.
Scientific information acquired through the mapping of the human genome will
accelerate the use and availability of genetic tests. This expansion will present
substantial planning and financial challenges to Ontario’s health care system, as well
as legal and ethical challenges to society. 
Currently, according to MOHLTC statistics, molecular genetic testing is
performed on one in 700 Ontario residents each year. This number is expected to
grow substantially in the coming years with the possibility that one in two
Ontarians may seek genetic testing in the near future1. 
More opportunities will soon be developed to prevent or treat diseases that have
a genetic predisposition through: 
n conventional therapies, 
n protein/enzyme replacement therapy, 
n gene therapies aimed at correcting the genetic abnormality, and
n pharmacogenetics (drugs tailored to a person’s genetic make-up). 
This anticipated rapid increase in genetic technology requires response strategies. 
The Evolution of Genetic Medicine
Genetic disorders result from alterations in full chromosomes, in chromosomal
segments, or in one or more of the approximately 40,000 genes which make up the
human genome. These disorders can be passed on to future generations during
reproduction.
Predictive genetic testing has focused increasing attention on gene changes
(mutations) rather than chromosomal disorders. A mutation usually changes a
gene’s ability to produce an essential protein or enzyme required for the body’s
function. The lack of this protein or enzyme results in disease. 
About 2-3% of children are born with a significant birth abnormality2,
approximately 0.6% of these are due to chromosomal anomalies, 1.4% to single
gene disorders and the remainder are multifactorial – due to genetic and
environmental factors. 
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1 The Genetics of Common Diseases. A Second Report to the National Health Service Central Research
and Development Committee on the New Genetics, 1995.
2 Harper, Peter S (1998) Practical Genetic Counselling, Butterworth and Heineman, Oxford, P.11.
Single gene disorders, where a single gene or pair of genes result in disease
development, would include: 
n Tay-Sachs disease (1 in 960 Ashkenazi Jews), 
n cystic fibrosis (1 in 2,500 Caucasians), and 
n Huntington Disease (1 in 10,000 – 1 in 20,000). 
There are more than 6,000 single gene disorders and about 870 of these can be
detected through molecular genetic tests3. For most of these disorders, the finding of
mutations in the gene or gene pair indicates a high probability of having the disease. 
In the past, geneticists tended to deal with rare disorders mainly seen in the
prenatal or paediatric populations. While this aspect of genetic medicine continues,
the practice has expanded to include genes for adult onset disorders. 
Genes for Adult Onset Disorders
This group of genes when tested before symptoms appear may predict disease with
certainty as in Huntington’s Disease, or may merely provide an estimate of risk for
developing the disease as with testing for breast cancer genes. 
The strength of the risk prediction may vary. For example, a woman carrying a
change in the BrCa1 gene may have an 80% chance of developing breast cancer4
while someone carrying a particular predisposition gene for coronary artery disease
may have a minimal increase in risk5.
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Type of tests
Type of disorders
Type of results
‘Old’ Genetics
Mainly diagnostic
Rare genetic disorders
Predominantly paediatric
Usually a high chance of having or
developing the disorder
Usually confirm or predict presence 
of disease but not severity
‘New’ Genetics
Mainly predictive
Common disorders with a genetic
component
Predominantly adult-onset
Low to high chance of developing 
the disorder
More complex risk predictions 
which may involve gene(s) and
environmental factors
3 GeneTests-Gene Clinics: Human Genetics Information Resource, 2001; Also Dr. R. Pagon in
correspondence with the Ministry of Health and Long-Term Care.
4 Easton DF, Bishop DT, et al. for the Breast Cancer Linkage Consortium. Genetic linkage analysis in
familial breast and ovarian cancer: results from 214 families. American Journal of Human Genetics
52(4): 678-701, 1993.
5 Winkelmann BR; Hager J (2000) Genetic variation in coronary heart disease and myocardial
infarction: methodological overview and clinical evidence. Pharmacogenomics;1(1):73-94
As biomedical science advances, more research is being directed at genetic
susceptibility to common adult onset disorders such as:
n breast cancer which affects 1 in 9 women, 
n coronary artery disease which affects 1 in 4 people, 
n Type II diabetes mellitus which affects 1 in 20 people, and 
n Alzheimer Disease which affects >1 in 206. 
In these disorders, susceptibility genes play a smaller role in the development of the
disease. Having one of these gene mutations does not guarantee that a person will
get the disease, but it does imply a susceptibility or predisposition.
The ten leading causes of death in Canada in 1997 were:
n Cancers (58,703 deaths)
n Heart disease (57,417)
n Cerebrovascual diseases (16,051)
n Chronic Obstructive Pulmonary Disease (COPD) (9,618) 
n Injury (8,626)
n Pneumonia/influenza (8,032)
n Diabetes (5,699)
n Neurogenerative diseases (5,049)
n Diseases of blood vessels (4,767)
n Psychoses (4,645).
With the exception of injury, at least a small percentage of nine of the leading causes
of death have a genetic component. For example, about 5% of people with cancer
have a genetic predisposition7. In infectious diseases such as influenza, pneumonia
or HIV/AIDS, genetic makeup plays a role in the immune system’s ability to fight
infection. For example, people who have one copy of the CCR5 mutant gene are less
susceptible to AIDS, and those with two copies are immune8.
It is important to remember that among the diseases listed above are chronic
illnesses with a genetic component such as diabetes and chronic obstructive
pulmonary disease. Such illnesses take a long-term toll on human health and have
related social and health care costs.
Environmental Factors
Environmental factors such as diet, exercise, and exposure to chemicals influence
many single or multiple gene disorders. Such disorders are called multifactorial.
Although the interaction between genetic and environmental factors is not well
understood, environmental factors may influence the age of onset, severity and
progression of the disorder. 
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6 Genetics: Basis for Medicine in the 21st Century, Dr. Achim Regenaur, Munich Reinsurance 
Company, Dr. Jorg Schmidtke Medical University Hanover
7 Harper, Peter S (1998). Practical Genetic Counselling, Butterworth and Heineman, Oxford, P.295
8 Dean M. et al (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion
allele of the CKR5 structural gene. Science 273, 1856-186
Environmental factors and interactions with other genes also play a role in
disease development. As a result, these multifactorial disorders tend to have lower
genetic risk and tend to be variable in their severity, age of onset and progression.
For example, mutations in genes such as those that control cholesterol
metabolism, transportation and its effect on cells will impact on the risk for
coronary artery disease (CAD). However, CAD also has a number of well-known
environmental risk factors including hypertension, obesity, diabetes, smoking and
lack of exercise9. Personal lifestyle choices play a crucial role in whether someone
with a predisposition to a disease will actually develop its symptoms. 
Tests for disorders such as CAD or diabetes will need to be incorporated into
complex risk calculations involving both genetic and environmental factors.
A few of the disorders being studied for their genetic origins/risk factors include:
n Alzheimer’s Disease10
n obesity11
n prostate cancer12
n cerebrovascular disease (stroke)13
n osteoporosis14 and 
n pre-eclampsia in pregnancy (affects 3-7% of pregnancies)15. 
Scientific Developments
The Human Genome Epidemiology Network
Genetic predisposition to disease represents only one cause of disease. Other areas of
research and population-based studies of the incidence and distribution of disease
are also needed to better target medical, behavioural and environmental
interventions. 
To meet this need, the American Centre for Disease Control set up the Human
Genome Epidemiology Network (HuGE)16 to assess the validity and determinants of
use of genetic tests in different populations17. 
HuGE analysis will not only help evaluate predictive genetic technologies but
will also help policy-makers identify the appropriate mix between genetic
interventions, disease prevention, health promotion and treatment. 
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9 Classical risk factors and emerging elements in the risk profile for coronary artery disease. 
Gensini GF; Comeglio M; Colella A (1998). Eur Heart J 1998 Feb;19 Suppl A:A53-61 
10 Nature Genetics vol 27 March 2001; 245
11 Nature Genetics vol 28 June 2001: 188
12 Nature Genetics vol 27 Februray 2001; 134
13 Roche and deCode, May 22, 2001
14 Roche and deCode, November 14, 2000
15 DeCode, September 19, 1999
16 HuGE Net, www.cdc/genetics/hugenet
17 Muin J. Khoury and Janice S. Dorman, The Human Genome Epidemiology Network (HuGE Net),
American Journal of Epidemiology, 1998;148:1-3, www.cdc/genetics/hugenet/about/editorial.htm
A Growing Number of Identified Genetic Disorders 
As of May 2001, approximately 93% of the human genome had been defined with
the remainder to be completed by 2003. This is no small feat given the 3.1 billion
base pairs that make up the human genome. 
To date, the achievements of genetic technology have been in their use as a
descriptive science – describing, mapping, sequencing and testing. Once the 
3.1 billion DNA base pairs of the human genome have been mapped, the next set of
goals for genetic technologies is to determine the function of various genes and to
find ways to intervene in the biological basis of disease and develop more effective
ways to diagnose, treat and prevent illness.
As the accompanying graph indicates, molecular genetic tests have been
developed based on knowledge of the relationship between gene function and
disease. As of October 2001, the Online Mendelian Inheritance in Man identified
13,060 gene loci that have been made public (www. ncbi.nlm.nih.gov). The final
number to be described is expected to approximate 40,000. 
Once a gene-disease relationship has been discovered, the stage is set for
developing a molecular genetic test. Currently, approximately 877 molecular genetic
tests are available internationally18. In Ontario, about 107 molecular genetic tests19
are being performed. (Appendix C identifies the laboratories and the molecular genetic
tests performed in Ontario.)
With genetic research expanding from the relatively rare monogenic disorders to
the more common multifactorial diseases, a significant increase in the number of
people seeking genetic testing is expected. Based on the prevalence of the more
common multifactorial diseases, one in two people in Ontario could eventually be
eligible for testing20. 
One of the most significant benefits of genomic research is that it provides an
opportunity to study the biology of all diseases. As research continues into tests,
treatments and the biology of these diseases, researchers will gain a better
understanding of the genetic mechanisms and the resulting production of proteins
responsible for changes in cell behaviour that give rise to disease. This
understanding may help researchers develop new treatments or prevention strategies
for all patients affected by a disease, not just those with a genetic predisposition.
A Growing Number of Predictive Genetic Tests
While it is not possible to predict with any certainty the number of new genetic tests
for adult onset diseases over the next decade, it is likely that it will represent an
ongoing pressure. The variety and volume of the new predictive genetic technologies
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that provide risk-based information about future health status is potentially quite
large. In addition, the risk determination for genetic changes in multifactorial
diseases will become extremely complex. 
Although most of the new discoveries in genomic medicine involve finding a
genetic cause for a medical disorder, some researchers are exploring the genetic link
to certain behavioural traits such as intelligence, criminality, sexual orientation,
aggressiveness and hostility21, 22, 23. 
Not only are ethical issues raised by the existence of these tests, they also raise
fundamental questions about what does and does not fall within the realm of
medicine and insured services. These tests also may result in the medicalisation of
the trait with the risk that the underlying difficult social issues such as poverty are
ignored.
Advances in Genetic Technology
The rapid evolution in our knowledge of the genome and advances in “molecular”
techniques has been accompanied by rapid expansion of the use of these techniques
in genomic medicine. Advances in automating molecular genetic techniques, as well
as in the storage and handling of genetic data by supercomputers, continue to
emerge. 
One of the most significant advances will be achieved through the use of
microchip arrays of molecular probes where it may soon be possible to test 400,000
gene samples in 5 minutes24. Over the next decades, this will significantly increase
the speed and number of test results, as well as lower the cost per sample. Both are
essential to the use of this technology. 
With this technology it will be possible to provide people with a personalized
genetic profile that outlines not only their predisposition to a variety of diseases, but
also the carrier and character traits they may pass on to future generations. 
This technology also generates major questions about informed consent in
medicine:
n Can patients fully consent to all of the tests being performed? 
n How will the risk for each genetic test in the microarray be determined? 
n How will lifestyle changes and surveillance programs for each patient be
determined? 
n How will broad-based genetic testing impact on follow-up care of 
healthy people?
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X chromosome and male sexual orientation, Science 1993; 261:320-326; See also Dean Hamer’s work
into other traits – http://rex.nci.nih.gov/RESEARCH/basic/biochem/hamer.htm.
23 Glenn McGee, The Perfect Baby: Parenthood in the New World of Cloning and Genetics, Rowman &
Littlefield Pub. Inc., 2000, 36
24 Nature Genetics v. 27 February 2001, www.nanogen.com/natgen
The latter will impact on the health system for single genetic tests as well.
Although advances in genetic technology make it possible to detect a broader
range of diseases, it poses the dilemma of being able to diagnose diseases for which
there is no known cure or treatment. In the experience with Huntington Disease
testing, families who wish to know their status benefit from the knowledge in terms
of life planning and for the relief from “not knowing”25. When this kind of testing is
done, the health care system must include necessary supports to individuals and
families, as well as legal protection from misuse of the information provided.
Next Stage Genomic Treatments and Cures 
The first phase of the human genome project – gene mapping – will lead to more
intensive efforts for developing new treatments and cures for many of today’s
common diseases. It is conceivable that over the coming decades, predictive genetic
tests will be accompanied by an array of genetic treatments including: 
n conventional therapies;
n pharmacogenetics – genetically tailored drugs to maximize effective response
while reducing unwanted side-effects;
n protein replacement therapy to provide missing hormones, enzymes, antigens or
other proteins that the body fails to provide (e.g. genetic engineering of bacteria
to make human insulin);
n new biologic material for invasive therapies (e.g. treating brain tumours with
modified herpes virus);
n genetic engineering of a person’s genetic structure by modifying the genes within
the somatic cells (body cells other than egg or sperm cells);
n modifying the germline (egg or sperm cells) of a patient to pass on altered
traits26. 
Pharmacogenetics 
Pharmacogenetics is a central focus of the pharmaceutical industry and on the near
horizon of clinical practice. Since differences in drug response are often genetically
determined, genetic testing will be used to fit medicines to individual genetic
profiles. This strategy is expected to avert problems such as adverse reactions. This
form of genetic testing will add a pressure to laboratories.
Pharmacogenetics could lead to the development of medications to treat specific
diseases based on a person’s particular genetic make-up, as well as presymptomatic
preventive therapies. If pharmacogenetics is to become an effective tool in clinical
practice, it will require genetic testing of individuals to identify the disease-related
mutations, as well as variants related to drug efficacy27. 
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Genome Project.
27 Nature 405, p. 857-865 (2000)
A review of recent pharmacogenetic research shows that a number of common
pre-disease or disease conditions are undergoing study, including:
n high cholesterol, 
n depression, 
n asthma, 
n hypertension, 
n breast cancer, 
n schizophrenia and migraine 28, 
n heart disease29, 
n vascular disorders such as peripheral arterial occlusive disease and
atherosclerosis (hardening of the arteries)30, and 
n rheumatoid arthritis31. 
While none of these has yet been proven in a clinical setting, they give an indication
of areas where genetic technology may impact on medical practice. 
Gene Therapy
Once causal links have been established between gene(s) and disease, gene therapies
offer another approach to treating genetic disorders. These therapies fall into the
four categories of:
n protein replacement therapy, 
n new biologic material, 
n genetic engineering of somatic cells, and 
n germline modification. 
Currently, a number of gene therapy protocols are being tested worldwide. Should a
therapy find its way into clinical practice, biochemical and molecular genetic tests
will be required to identify the gene mutation and the outcome of the therapy. 
Genetic Reductionism
With rapid and exciting developments in genetic technology, there may be a
tendency to exaggerate the role this technology will have in changing health care
outcomes for people. 
The Advisory Committee recommends a cautious approach to embracing and
implementing genetic technologies. This approach recognizes the complex
interactions of genes and the environment and is mindful of the uncertainties of
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genetic testing. It also recognizes that, depending on the disorder, other approaches
to disease control, such as population-based health promotion, could be more
appropriate and effective than an approach based on genetic testing.
For example, most hereditary breast and ovarian cancers are due to mutations in
the BRCA 1 and BRCA 2 genes. It is also possible to detect individuals at risk for
hereditary colon cancer syndromes. But only 10% of people diagnosed with breast,
ovarian or colon cancer has a hereditary disposition to these diseases. Genetic
testing by itself is not an absolute predictor of these common illnesses. Other factors
including environmental influences play a vital role.
In common diseases such as coronary artery disease, genetic changes may reveal
predisposition, but the strategy for dealing with the disease may be population-
based health promotion and prevention programs.
Governments delivering health care must determine what proportion of health
care resources should be devoted to detecting genetic predictors when these
predictors are not absolute and other known, sometimes preventable, influences
remain in the development of diseases. 
Effects On The Health System
Advances in the biomedical science of human genetics, as well as in the technology,
will affect the health system in a variety of ways:
n the volume and variety of the new predictive genetic technologies that provide
risk-based information is potentially quite large. This means that the number of
people seeking genetic tests and patients seeking health care will increase;
n genetic testing for traits rather than diseases, raises serious questions about the
definitions of medicine and medical necessity;
n advances in microarray chip technology may not only increase public demand
for the technology, but raise issues about the content and use of genetic
information;
n the need for trained geneticists, genetic counsellors, and laboratory staff with
new expertise will increase;
n predictive genetic medicine will result in greater emphasis on health promotion
rather than medical treatment;
n the ordering of a test must not be divorced from the education, interpretation
and counselling which must accompany the testing for patient well-being.
The Ontario Public’s Views About Genetics
In September 2001, the province commissioned Ipsos-Reid to conduct a telephone
survey of the public’s level of knowledge and views on human genetic testing. One
thousand adults were surveyed32.
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89% of those surveyed stated that they were personally interested in this
important subject.
The survey found that 89% of Ontarians are favourable in their overall opinion
of human genetic testing. They are willing to admit that they know little about the
issue, but they are interested in finding out more about it. They are aware that
genetic predictions are not definitive pre-determinants, but rather that genetics may
play a role in some health conditions and diseases. 
The public’s favourable views stem from optimistic perceptions of the direct,
health related benefits that could stem from human genetic testing – that genetic
testing can be used for detecting/curing/preventing diseases and so are beneficial to
humans for the future. Genetic testing is perceived as potentially helping doctors
diagnose disease, helping medical researchers develop new medical innovations, and
helping governments plan and develop health care programs. 
Public Perceptions
The public has positive views about informing people of their likelihood of
developing disease to permit preventive actions, as well as helping parents advise
their children about an inherited family disease. 
n 78% felt that new genetic developments will mean children are healthier and
free from inherited disabilities. 
n 79% felt it was appropriate for couples planning a family to use genetic
information if their children are likely to have an inherited disability or life-
limiting illness. 
n 40% were concerned that research in human genetics may be tampering with
nature and is potentially unethical. 
Privacy a Concern
People surveyed emphasized the need to ensure that genetic testing does not result
in discrimination in employment, insurance, or access to services. 
n 86% of those surveyed strongly felt that people should always be asked for their
permission for their blood or tissues to be used in a genetic test, or for genetic
research. 
n 97% agreed that information should only be included in a database if an
individual has given consent. 
n 87% believed that consent must be given for each specific new research initiative
for which a sample is to be used. 
n 79% agreed that genetic databases and information should only be stored in
Canada. 
n 66% agreed that Canadian genetic databases should be publicly owned or
controlled. 
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Far-Reaching Effects
n 38% are confident that rules and regulations are keeping pace with
developments and research in genetic testing. 
n 54% of respondents believe the federal government should be making guidelines,
rules and regulations that will guide the use of human genetic testing. 
n 34% believe that international organizations have a role.
They believe that the provincial government has a role in paying for genetic services
but acknowledge that there may be instances where payments for tests should be left
with individuals. For example, if the testing is for character traits or behaviours
rather than for medical conditions. They recognize that the funding of genetic
testing research and regulation may be national and/or international responsibilities. 
Patenting of Human Genetic Materials and Genetic Testing
While they saw a strong role for the private sector in genetic research to develop
treatments, respondents also recognized the dilemma in genetic patenting. 
n 64% felt that if a private company invested large amounts of time and money to
develop a new way to use human genetic information for genetic testing, they
should have the right to charge for its use.
n Only 51% expressed a favourable view of a company’s ability to patent genetic
material identified to develop the tests. 
The Provincial Genetics Program 
Ontario has developed an international profile in genetics research. Significant
funding for genetics research continues to foster new discoveries at several Ontario
Research Laboratories including: 
n the Hospital for Sick Children, 
n the Samuel Lunenfeld Research Institute, 
n the Ontario Cancer Institute, 
n John P. Robarts Research Institute, and 
n the Children’s Hospital of Eastern Ontario. 
Ontario’s scientists have been responsible for identifying genes for cystic fibrosis,
retinoblastoma and myotonic dystrophy and are at the forefront of proteomic
research that explores proteins made by genes that are responsible for diseases.
Providing a sound clinical infrastructure should improve opportunities for
translational research and continue to mirror the excellence that clinicians and
scientists in the province have achieved in this area. 
While genetics research was not in the terms of reference for the Advisory
Committee, it is important for the province to appreciate the outstanding
contributions that Ontario’s scientists and clinicians continue to make in this area.
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For the past 25 years, Ontario has provided genetic services as a priority
program through a cooperative interlinked series of services in hospitals and public
health units across Ontario. 
Ontario’s genetics program is believed to be the most comprehensive and
coordinated in Canada. It consists of initiatives in:
n genetic diagnosis, 
n genetic counselling, 
n genetic testing, 
n prenatal genetics, and 
n metabolic services.
It operates under practice guidelines developed by:
n the Canadian College of Medical Genetics, 
n the Canadian Association of Genetic Counsellors, 
n the American Society of Human Genetics, 
n the Society of Genetic Counsellors in the United States, and 
n the American College of Medical Genetics. 
Professional bodies in other areas of medicine have set guidelines and policies for a
variety of conditions and situations that directly relate to the practice of genetics. For
example, the American College of Obstetrics and Gynecology has guidelines on cystic
fibrosis screening, and the Canadian College of Medical Geneticists and the Society of
Obstetrics and Gynecology of Canada have created guidelines for prenatal diagnosis.
While medical geneticists order most genetic tests, some are ordered by family
physicians and other specialists who may also provide counselling without referral
to a genetics centre. 
The current regional genetics network consists of nine linked regional genetics
centres made up of:
n 19 clinical genetic clinics,
n 11 cytogenetic laboratories,
n 10 biochemical genetic testing and maternal serum screening laboratories, and 
n 8 molecular/DNA genetics laboratories. 
Regional genetic centres are located in: 
n Hamilton – Hamilton Health Sciences Corporation, 
n Kingston – Kingston General Hospital, 
n London – London Health Sciences Centre, 
n Mississauga – Credit Valley Hospital, 
n North York – North York General Hospital, 
n Northern Ontario – Sudbury Regional Hospital, 
n Oshawa – Lakeridge Health Corporation , 
n Ottawa – Children’s Hospital of Eastern Ontario, and
n Toronto – Mount Sinai Hospital and the Hospital for Sick Children.
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All centres offer coordinated clinical and laboratory services. Each has various
genetic service components. Along with 10 clinical outreach centres, these centres
serve the province on a regional basis. 
Current base funding for the Provincial Regional Genetics Program is
approximately $39 million. Genetic testing done in the course of physician care
outside of the program is not included in this amount. In 2000/2001, OHIP
payments of $1.460 million were made for individual and family counselling and for
laboratory testing for common genetic disorders.
To date, genetically based testing has been introduced into medical practice as
new testing became available – without a consistent policy framework and with
varying levels of scrutiny. The complexity of the results and their implications
means that interpreting them in a meaningful way can be enormously difficult. 
While any physician may order genetic tests, the interpretation of results can be
complicated and ambiguous results are possible. Test results that predict risk can be
difficult for patients to translate into decisions about their care and reproductive
behaviour. As a result, certain genetic tests, such as those for breast and ovarian cancer,
Huntington Disease and early onset Alzheimer disease, are usually provided through
genetic centres or specialty clinics where counselling and support are available.
Personnel in Genetic Services
The Provincial Regional Genetics Program currently employs 28 MD and 22 PhD
geneticists. Ontario currently has over 100 genetic counsellors spread throughout a
network of hospitals, cancer centres and public health unit clinics. The program
currently employs close to 200 laboratory personnel. Family physicians and
specialists have always provided some genetic services in their offices without
referral to a genetic centre and it is expected that this role will increase over time.
Clinical geneticists are physicians who practice medical genetics. They provide
diagnosis and management of genetic conditions, usually in consultation with
primary care physicians or other specialists. They supervise services provided by
genetic counsellors and nurses.
Genetic counselors counsel and support individuals and families seeking genetic
advice. Genetic counsellors may be trained to a Masters level through a university
program, or they may be registered nurses who have learned genetics in the course
of their work. 
Each genetic centre has a Head of Genetic Services. Several have associated
psychosocial staff to provide supportive counselling and treatment to their patients.
Unfortunately, there are few mental health personnel at this time with knowledge of
genetics, making referrals to mental health professionals difficult. 
Some centres have other support personnel such as the dieticians at the Hospital
for Sick Children who provide preventive care advice to children and adults with
inborn errors of metabolism.
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Training of Genetic Personnel
The Canadian College of Medical Genetics has an accreditation program for training
medical and biochemical geneticists. It also certifies PhD geneticists in cytogenetics
and molecular genetics. Physicians must complete at least three years of
postgraduate training in an accredited residency program before completing a two-
year fellowship in clinical genetics at an accredited centre. Fellowship in the college
follows successful completion of an examination. Every two years, there are seven to
eight new fellows in each of clinical genetics, molecular genetics and cytogenetics,
and zero to one in biochemical.genetics.
The Royal College of Physicians and Surgeons (RCPS) now offers a specialty-
training program in medical genetics for physicians. Up until 1996, physicians with
established credentials in medical genetics could take the exam for the Royal
College. Since then, the exams can only be taken after a five-year residency in
medical genetics. There are one to five graduates across Canada each year. 1992
was the first year that the Royal College qualified candidates as specialists in
medical genetics. 
Laboratory physicians may have completed training programs in anatomical
pathology, general pathology, hematopathology, hematology and clinical chemistry
accredited by the RCPS. Laboratory scientists who do not have a medical degree are
not eligible for recognition by the RCPS.
McGill University, the University of Toronto and the University of British
Columbia offer a two-year Masters Degree in Genetic Counselling following the
completion of an undergraduate degree. Approximately 12 genetic counsellors
graduate from these programs each year. Some Canadians train in American
programs, where there are about 125 graduates a year.
Family physicians receive their training in genetics through the study of the
biological sciences. However, training in genetics is not a core part of the curriculum
in Ontario’s Faculties of Medicine.
Technologists who work in Ontario genetics laboratories must be licensed by the
Ontario College of Medical Laboratory Technologists. Two facilities in Canada, the
Michener Institute in Toronto and the BC Institute of Technology, currently offer
training in genetics technology. The Michener Institute trains eight individuals from
Ontario per year in a combined cytogenetics and molecular genetics program. 
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Section 2: Sub-Committee Reports
and Recommendations
The Provincial Advisory Committee on New Predictive Genetic Technologies set up
six sub-committees to assemble the framework for introducing new genetic predictive
technologies. In developing the framework, the sub-committees considered:
n criteria to assess the validity and utility of a new technology,
n guidelines for implementation, 
n guidelines for ongoing monitoring and evaluation, 
n human and capital resource requirements for the short term and over five years,
n translation of research into service in the short term and over five years,
n approaches taken by other jurisdictions,
n commercialization and the role of the private sector, and 
n data management.
Report of The Legal and Ethical Issues Sub-Committee 
Objectives
To identify social, legal and ethical issues that require regulatory and professional
intervention. 
n To specify options for new regulatory structures and interventions. 
n To identify areas where further analysis and debate is needed. 
Findings
Ethical and Legal Considerations 
Ethical and legal issues permeate every phase of the development of new forms of
genetic testing – from the development of genetic knowledge through research, the
development of quality standards for laboratory testing and decisions regarding health
care coverage for genetic testing, to the provision of clinical care in genetics and the
development of a regulatory structure for the professions providing genetic services. 
Though many of the issues raised in the context of genetic testing are not
entirely new and unique, the specific characteristics of genetic testing and genetic
information do raise particular social and ethical issues that require a variety of
regulatory and professional interventions and warrant the development of new
regulatory structures and interventions.
In the coming years, legislative changes may also be warranted to address the
ethical, legal and social issues of genetics. As important is adapting existing or
newly proposed regulatory structures to enable them to address these issues in an
accountable and transparent manner. 
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Why Do Genetic Information and Genetic Testing Warrant 
Special Attention?
Genetic information brings the ethical, legal and social issues involved in the use of
health information to a different level. Genetic tests provide more detailed risk
information than most other tests, generating new grounds for potential
discrimination and stigmatization. 
Because one’s genetic information reveals information about one’s family, genetic
testing increases dilemmas surrounding the duty to inform third parties, such as
family members, of particular health risks.
Genetic information impacts in particular ways on communities, for example by
opening the door to the verification of historical and cultural knowledge and by
potentially increasing risks for stigmatization and discrimination. 
Genetics also gives us a greater volume of information, which can be extracted
from one sample and then kept indefinitely. At the same time, the nature of the
information is such that it generally only reveals a person’s risk for disease, and not
his or her current health status. However, risk information has become a powerful
tool in the current social and cultural environment. Genetic information will be
particularly attractive because of its potential to provide more detailed data. As a
result, the ‘not yet ill’ may be increasingly vulnerable in various areas of social life. 
These “exacerbated problems” also increasingly play out in a specific commercial
and international health care context. Commercial interests may impact on the
development of genetic research, the promotion of genetic technologies, the provision
of genetic and other health care, and the use of genetic information by third parties.
Patent rights over genetic research may have a significant impact on the conduct of
research and on the availability of genetic testing within a health care setting. 
The international context has also changed. Genetic information does not
respect borders, nor does it answer to customs officers, particularly in the context of
a globalizing economy. 
Genetic developments have not only been enabled by, but also take place in a
new technological environment. Computer and other information technologies, for
example, are crucial components of discoveries in genetics. They have simplified the
storage and transfer of genetic information, accelerated the research and testing
process, and made testing less invasive and less burdensome. 
People can easily provide the necessary samples and send them in for testing,
regardless of state or provincial borders. This is bound to have repercussions on the
demand for health care services as people will try to access health services in the
province based on genetic test results accessed elsewhere. 
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Recommendations
The Legal and Ethical Sub-Committee offers recommendations in the areas of:
n discrimination and stigmatization,
n insurance and employment,
n the regulation of research,
n laboratory testing,
n allocation of resources for genetics,
n patents, commercialization and direct marketing of genetic testing,
n regulation and liability of genetic counsellors,
n clinical issues,
n storing genetic information and genetic material, and 
n privacy and confidentiality.
Discrimination and Stigmatization Issues
Because genetic tests can reveal information about the future health risks of an
individual, and potentially, information about personality traits and other personal
characteristics, its use opens the door to discrimination and stigmatization. 
Insurance companies could use, and to some extent already do use, genetic
information to increase premiums or to deny coverage on the basis of risk status.
At the same time, genetic test results could benefit people with family histories of
disease to obtain better coverage. The interests of the insurance industry in avoiding
adverse selection have to be balanced against society’s interest to avoid
discrimination. 
Employers could use genetic information to identify at-risk employees or
applicants, and deny them employment opportunities based on this information.
At the same time, some genetic tests might also be used as an occupational health
and safety tool. 
Genetic information could also be used in immigration, education, and by
financial institutions and adoption agencies. Genetic discrimination and the
financial and social consequences of being affected by a ‘genetic risk’ could create
pressure towards subtle, passive eugenics, if the potential social and financial costs
of a genetic risk status become unbearable. 
Recommendations
Human rights legislation should be amended to make sure that people with a
genetic predisposition or susceptibility are adequately protected against
discrimination. Such an amendment may need to include a specific prohibited
ground of discrimination, covering the perception of future illness or disability. 
The Legislature should consider amending the Human Rights Code to prevent
discrimination on the basis of genetic traits. This could be done by explicitly
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including “genetic trait” as a prohibited ground of discrimination in Part 1, or, as
the Ontario Law Reform Commission recommended, by amending the definition of
“because of handicap” in section 10(1) so that it provides as follows:
10.–(I) In Part I and in this Part. 
“because of handicap” means for the reason that the person has or has had,
or is believed to have or have had, or for the reason that it is believed that the
person will have 
(a) any degree of physical disability, infirmity, malformation or
disfigurement that is caused by bodily injury, birth defect or illness
and without limiting the generality of the foregoing, including
diabetes mellitus, epilepsy, any degree of paralysis, amputation, lack
of physical coordination, blindness or visual impediment, deafness or
hearing impediment, muteness or speech impediment, or physical
reliance on a guide dog or on a wheelchair or other remedial
appliance or device,
(b) a condition of mental retardation or impairment,
(c) a learning disability, or a dysfunction in one or more of the processes
involved in understanding or using symbols or spoken language, 
(d) a mental disorder, or 
(e) an injury or disability for which benefits were claimed or received
under the Workers’ Compensation Act. 
If the Legislature adopts the latter course of action, the Human Rights Commission
should issue an interpretive rule providing that genetic conditions, both present and
future, fall within the scope of its legislative protection.
In addition, the government should consider establishing measures that are
proactive in avoiding discriminatory uses of genetic information. Human rights
commissions and specialized commissions dealing with insurance and employment
should be involved in determining what types of testing can be introduced and what
types of genetic information can be used in the context of insurance, employment
and any other area where discrimination could occur on the basis of genetics. 
The government should establish an approval system for using genetic testing
and genetic information in insurance, employment, adoption, education and any
other areas outside of health care, where using genetic testing and genetic
information could have negative or undesirable social consequences. If genetic
testing and information were to be used in these contexts, it would have to be with
the approval of a governmentally approved decision-making body which is
interdisciplinary in nature and represents the various interests at stake.
If a Provincial Advisory Committee on Genetics is re-established, addressing all
issues of discrimination and stigmatization through liaison with other relevant
partners should be one of the first tasks undertaken.
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Insurance and Employment Issues 
Many Canadians have identified the issue of insurance and genetic information as an
immediate concern. Internationally, several jurisdictions have taken regulatory or
legislative measures to curb genetic discrimination in the context of genetics. In
other jurisdictions, official reports have urged governments to take action.
Many American states have enacted specific genetic discrimination statutes. But
these focus mainly on health insurance and are enacted in a different health care
environment. The absence of universal health care in most states makes it an
immediate concern for them to protect people’s access to health care insurance.
Many health care specialists suggest that the further development of genetic testing
will make it crucial for the United States to move towards publicly funded health
care, accessible to all regardless of their risk status.
In Ontario, many health care products are currently being provided through
private insurance. Many drugs, for example, are not covered by OHIP. Drug coverage
will increase in importance with the further development of pharmaco-genomics –
increasing the risk that discrimination in private insurance will affect access to
health care. 
In Europe, several countries (including Austria, Belgium, France, Denmark,
Luxemburg, the Netherlands and Norway) have prohibited or restricted the use of
genetic information for insurance purposes. Some of these countries also prohibit
applicants from submitting the results of potentially favourable genetic tests to
insurance companies. This avoids positive selection where individual applicants
submit a good risk-profile to obtain insurance – circumventing the prohibition
against asking for test results. 
Genetic discrimination in employment has not been as extensively dealt with by
other jurisdictions but has been identified as a serious potential concern. In
February 2001, the U.S. Equal Employment Opportunity Commission filed its first
challenge under the Americans with Disabilities Act against a railway company that
conducted genetic tests of its employees for Carpal Tunnel Syndrome. Because the
pressure to introduce genetic testing in employment will likely increase in the
coming years, this issue needs to be addressed now. 
The 1996 European Convention on Human Rights and Biomedicine will be a
driving force behind further legislative action in this area in Europe. It explicitly
prohibits, in article 11, “any form of discrimination against a person on grounds of
his or her genetic heritage.” Article 12 prescribes that genetic tests can only be
performed for health care or scientific purposes. It also specifies that appropriate
genetic counselling should be provided. 
Its explanatory report specifies that even a person’s consent cannot be used to
justify a genetic test conducted for other than health or research related purposes. In
Europe, there is a clear development towards introducing legal tools to address the
issue of discrimination. Signatories to the Convention have to introduce legislation
for the state to respect the provisions of the Convention. 
The Committee concluded that the issue of discrimination is one of the most
serious and pressing issues raised by new genetic technologies, to be addressed. 
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Human Rights Issues
The Committee felt that the magnitude of the issue of discrimination was so great
that government should expand the power of the Human Rights Commission or
establish a special commission to evaluate specific genetic tests and types of genetic
information before their use for insurance or employment purposes.
The commission should include geneticists, actuarial specialists, members of the
public and lay organizations, lawyers and ethicists, with no financial interests in, or
contractual relations with, the industries potentially affected by its decisions.
Industry and labour organizations would also be represented.
The commission’s decisions would be informed by standards of accuracy,
validity, and predictive value for the use of genetic information in insurance and
employment. Any request would have to be supported by credible scientific and
actuarial data that would be assessed by the commission in light of the potential
social, ethical and legal consequences of using the test or information. 
The task of the commission would be similar to that of the evaluation committee
charged with the general evaluation of proposed genetic tests, but it would focus on the
specific use of genetic testing and genetic information in insurance or employment.
As an interim measure, the government should urge the insurance industry to set
up a commission of experts, with representatives of industry, lay organizations and the
public, as well as specialists in actuarial sciences, law and ethics, who are independent
from and have no financial interests in the insurance industry. This commission could
make specific recommendations on using genetic information for insurance purposes. 
The government should consider implementing a moratorium that would
prevent insurance companies and employers from using genetic information to
determine eligibility for insurance or employment. 
A moratorium would provide time for the government to consult and work with
interested stakeholders to develop policies and practices for employers and the
insurance industry using genetic information. The moratorium should remain in
effect until proper policies and processes for the use of genetic information in these
contexts are implemented.
Since some tests for employment-related susceptibilities have already been
developed which could benefit employees, employers could discuss with the
Provincial Committee the appropriateness of offering genetic tests that could protect
employees against workplace related harms. Such tests should not be a condition for
employment but should be offered for employees who test positive to obtain
reasonable accommodation. 
In the insurance context, the terms of the moratorium should be discussed with
the insurance industry. It may be appropriate to allow people with a family history
of disease to use genetic test results to show that that their risk is low. It would also
be appropriate to link the moratorium to a maximum amount of coverage. The
moratorium could apply to most life and additional health insurance policies, but
not to those of overly high value. 
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In addition, the government could urge the insurance industry to immediately
introduce a policy that no genetic test results obtained in research will be used for
determining insurance premiums. This would avoid criticism that valuable research
is being affected by people’s concern about potential insurance implications. 
The Regulation of Research 
Canada currently has no clear statutory regime for reviewing research involving
humans. In 1997, the three major federal funding agencies issued the Tri-Council
Policy Statement on Ethical Conduct for Research Involving Humans, a set of guidelines
that sets out acceptable practices and ethical standards for research involving
humans. Health Canada has also declared that research supporting an application for
drug approval has to respect this Statement, as well as the International Conference on
Harmonization Tripartite Guideline for Good Clinical Practice (ICH guidelines). 
These guidelines are the latest initiatives within a gradual development of
research review and research ethics standards in Canada. 
Research Ethics Boards
Many Research Ethics Boards (REBs) have developed significant expertise in
reviewing research protocols for adherence to ethical standards. Many REBs and
institutions have also been involved in teaching programs and workshops to educate
researcher and REB members. 
The duties of REBs and the expectations towards them have increased over time,
with the result that many are overburdened and suffer from strained resources. 
More importantly, no statutory regime regulates the establishment, membership,
decision-making process, administrative structure, and regulatory powers of these
REBs. There is also no system of registration of REBs and no information on how
many REBs function in the province or in the country. 
Funding agencies and Health Canada recognize REBs as playing a crucial role in
the review process but no clear structure or enforcement mechanisms are in place to
ensure that REBs function appropriately and that they, the researchers and the
institutions in which they operate, respect the guidelines. 
Until recently, the National Council on Ethics in Human Research (NCEHR) was
the main national body with a mandate to promote research ethics standards across
the country. However, the NCEHR has no clear regulatory power and has never been
significantly funded so as to enable it to play a very active role. 
Publicly Funded Research 
The Tri-Council Policy Statement only binds institutions and researchers with respect
to funded research. It does not have force of law. 
If researchers and research institutes do not respect the Statement, they could be
sanctioned by the withdrawal of funding by the funding agencies. However, the
funding agencies have little control on how REBs in Canada apply the Statement. In
the absence of a clear process and reporting structure, it is unclear how and when
the funding agencies would be informed of violations of the Statement.
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Privately Funded Research
The ICH guidelines do not cover all forms of private research, but only private
research that aims at an application for drug approval. 
Health Canada requires that those who are seeking approval of a new drug
obtain prior REB approval for the clinical trial that supports their application. But
applicants only have to answer in the affirmative that they obtained such approval.
The system relies entirely on self-reporting and there is little or no control on the
actual review process. 
There seems to be no legally enforceable obligation to obtain an external REB
approval before engaging in non-funded, private research that will not result in
drug approval. 
Research Funded by the National Institutes of Health
Institutions conducting research funded by the U.S. National Institutes of Health are
subject to more rigorous control of the REBs by the Office of Human Research
Protection. Although more detailed regulations exist in the U.S., several official
reports have pointed out that the overseeing of research ethics review is weak and
has several loopholes.
Lack of Regulatory Supervision
The potential consequences of the lack of regulatory overseeing of research ethics
review should not be underestimated. The regulatory and funding agencies recognize
that REBs have as their primary duty the protection of the rights and well-being of
research participants. Health Canada has recognized that REBs have a crucial role to
play in, for example, assessing the risks and benefits of a study, preventing the
potential impact of conflicts of interests and in monitoring ongoing studies. 
In the review process and in the monitoring of studies, REBs have to take into
consideration adverse event reports that relate to the drugs or therapies being tested.
Recent reports have indicated that adverse events are underreported and that it is
unclear how many adverse events in research really occur. 
Research mishaps in the United States, including the deaths of healthy or only
mildly ill research participants who died as the result of research participation, have
forced regulatory agencies to suspend the research activities in some of its most
prestigious institutions33. While Canada has not been confronted with the same
public controversies involving deaths of research participants, it is not clear that the
research context is so different that it could not happen here. 
Recent controversies related to conflict of interests in research indicate that
similar pressures do exist in the research context as in the U.S. There is also less
regulatory supervision which might make it more difficult to have public knowledge
about mishaps in Canada.
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33 For a discussion of a recent U.S. case and an analysis of whether Canadian rules and procedures for
conducting clinical trials on voluntary research subjects would have been any better, see: Richard Ian
Ogilvie (Nov. 13, 2001) “The death of a volunteer research subject: lessons to be learned” CMAJ
165(10) 1335-1337).
At this time, REBs are operating differently across the province and the country
and there is little control on their functioning, decision-making, membership and
training. As well, many REBs are struggling with issues around conflicts of interest
within their boards. 
Formal regulation of research review is of interest to everyone who would be
protected by this regulation, including the public, research subjects, researchers and
the many members of REBs in Ontario and Canada. The regulatory vacuum creates
uncertainty and harms the efficient, solid and coherent review of research protocols
and may hamper research. It also may impact on how Ontario researchers can
collaborate internationally. 
The lack of clear regulatory structure and supervision is of significant
importance in the area of genetics. Many genetic programs are first introduced in the
research setting. Potentially harmful genetic information becomes available in these
research projects but there is no clear standard of review. Expertise and knowledge
in genetics and in the ethical and legal issues raised by genetics are often lacking on
REBs. A central review board may be required for certain types of high-risk research
and for research invoking significant social concerns. 
Health Canada’s Ethics Division is currently looking into the need for regulation
and Ontario’s efforts should be harmonized with these efforts. Other provinces
(including Newfoundland and Quebec) are also implementing, or considering,
stricter regulation in this area. Internationally, there is a clear move towards the
development of regulatory structures around research. 
Recommendation
While the Committee did not have consensus on how to deal with this issue, it
agreed that the growing prevalence of genetic testing in research makes the need
even more pressing to examine what research is approved and the conditions for
that approval. 
At a minimum, the government should ensure that no genetic testing is
undertaken for research in Ontario without adequate research ethics review by an
independent and accountable REB. In looking into the development of an adequate
research review system, Ontario should coordinate its efforts with those of the
federal government and other provinces. The current regulatory structure or lack of
structure is a cause for concern.
Laboratory Testing
In Ontario, the present evaluation process for approval of new laboratory testing
focuses on ensuring the quality and scientific validity of tests. The evaluation
process does not necessarily address the informational and social risks associated
with a particular test, or the ethical and legal issues. 
Few would question the value of a genetic test that would enable us to identify
an increased risk of developing a particular form of treatable cancer, or a preventable
disease. The notion of disease is however expandable. Genetic research could lead to
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the development of a test that would reveal an increased chance of having a
particular personality or behavioral trait, such as aggressiveness. Parents could use
such a test and decide to abort their “affected” foetus. 
The determination of how to weigh potential benefits and harms of introducing
a new test is not something that ought to be done only by those having technical
expertise. It involves a weighing of social and ethical issues which requires that the
public be represented within the decision-making process, as is proposed in this
report. 
It would be wise to have societal debate about these issues even before allowing the
introduction of such tests, whether insured or not. An evaluation of the social and
ethical impacts of a proposed genetic test should be conducted before the test is
approved for use. The review structure for genetic laboratory testing should be adapted
to include an appropriate and solid review of the ethical, legal and social issues. 
The sub-committee recommends that no genetic test should be introduced in
Ontario unless a thorough evaluation of the ethical, legal and social impacts of the
proposed test has been conducted. The committee responsible for this evaluation
should include people who are knowledgeable about the scientific, ethical, legal and
social issues, as well as members of the public and lay organizations. 
Allocation of Resources for Genetics
Although genetic testing has the potential to improve human health, the costs of
genetic testing and genetic services can be very high. 
An appropriate balance must be struck between investing public financial
resources in genetic testing and services and in other health services and
technologies including those related to the social determinants of health. When
evaluating a service that will be beneficial, determinations must also be made to
ensure that all individuals will have equitable access to this service, regardless of
socio-economic status or place of residence. 
Patents, Commercialization and Direct Marketing of Genetic Testing 
Patenting genes and genetic tests
Increasingly, patent protection is sought for genetic tests, as well as for the genes
that are the subject matter of genetic tests. While products of nature are
unpatentable, courts have held that genes that have been isolated, purified or
modified are patentable. To be patented, these “inventions” would still have to fulfill
the patent requirements of disclosure, novelty, non-obviousness and utility. 
Once an invention is patented, the patent holder has the exclusive right to
make, use or sell it for 20 years. Given this monopoly, it is imperative that patents
on genes and genetic tests are validly granted and that there is no deviation from the
traditional requirements of patentability.
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Another major concern is that patents not restrict the availability of genetic
testing by facilitating monopolistic pricing and restrictive licensing agreements. It is
important to determine whether the Patent Act should be amended to ensure some
control over the price of patented tests and access. 
Ontario has already been confronted with the impact that gene patents may have
on the costs of health care in the province, in the controversy around BRCA1+2
testing. With the further development of genetic testing, this may create a significant
financial burden to the health care system or may make it harder for the provincial
governments to decide to cover new genetic tests. 
Depending upon the type of regulatory regime that is desirable for genetic tests,
it may be important to enable domestic labs to obtain licenses to provide the tests in
Canada instead of having samples sent for testing abroad. 
Although statutory changes would require careful study, they would not
necessarily require a rethinking of our basic patent system. Analogies can be made
to existing provisions about the abuse of patents, government use of patents, and
the patented medicines regime. 
Gene patents also raise more fundamental questions about our patent system.
Patents provide incentives for innovation by allowing the patent holder to recoup
the cost of research and development, as well as to realize a return on this
investment. This monopoly is granted to the patent holder in exchange for the full
disclosure of the invention so that this knowledge can become a part of the public
sphere and contribute to further innovations. In this way, patent rights promote the
public interest and can be vital to our research industry. 
However, some people question whether patents on genes and gene fragments
impede rather than facilitate innovation by providing monopolistic rights over the
basic building blocks of research. There are many other related questions about
whether patent law provides the correct incentives in the area of genetics or whether
it overcompensates patent holders. 
But private companies are not the only ones providing financial and other support
for the research that leads to patents. In many cases, research takes place in public
institutions, partly funded by federal and provincial governments. Other costs of
research, for example when research subjects are treated in hospital for adverse events,
are carried by the publicly funded health care system. By participating as research
subjects, individual Ontario citizens also contribute to the development of patents. 
It is important to determine to what extent all of these public contributions are
recognized and rewarded in the current system. The government could stimulate an
open debate among interested parties about this issue. 
Fundamental questions have also been raised about the nature of genes and gene
sequences. Commentators have objected to the idea that individuals or companies
would be able to have patent rights over these ‘fundamental building blocks of life’. 
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These complex economic issues are beyond the competence of the sub-
committee but it is important that this area receive serious attention. Overprotection
means that the tests will cost more than they should; underprotection means that
fewer tests may be developed.
While it may be legally difficult to distinguish patents on isolated genes from
existing patents on chemical compounds, it is important that this widely expressed
concern be addressed in public debate. The government of Ontario has already
taken initiative in this area and should continue to take part in this debate. 
Countries throughout the world have, or are undertaking, a variety of options to
address the problems currently raised by genetic testing. The sub-committee
supports the Ontario government in urging that these options be considered by the
Canadian government through a public debate.
Commercialization and Direct Marketing
Direct patient access to commercial genetic testing raises important issues about the
adequacy of pre-test information and counselling, which are essential for informed
consent, and for post-test counselling and support especially where the test is
positive for carrier status or susceptibility to a disorder. 
This testing will likely have spillover effects on the publicly funded health care
service within the province, particularly in the areas of genetic counselling and
follow-up care. The commercial availability of genetic testing could result in
aggressive marketing strategies, potentially promoting over-use of genetic testing,
determining which tests are available irrespective of their utility for health care, and
inhibiting planning.
As a first step, the government of Ontario should engage in discussions with the
government of Canada regarding patents, direct to consumer marketing and other
areas of federal jurisdiction related to the commercialization of genetic tests, which
also have direct and pressing implications for the delivery of health care in Ontario. 
Regulation and Liability of Genetic Counsellors 
The significant role that genetic counsellors play in genetic testing services is
gradually being reflected through policy. The Canadian Association of Genetic
Counsellors has developed guidelines on the scope of practice of genetic
counsellors, as well as a certification procedure for its members. Genetic centres also
have developed their own policies and standards of practice. 
However, there is currently no statutory regime for the regulation of the practice
of genetic counselling in Canada. Ontario’s Regulated Health Professions Act does not
apply to genetic counsellors, nor is there any licensing procedure for them
comparable to the provincial colleges of physicians and surgeons’ licensing of
physician-geneticists to practice medicine. 
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In contrast to other health professionals, genetic counsellors do not have their
own malpractice insurance. Institutions and physician-geneticists who employ
genetic counsellors bear legal responsibility for their actions, provided they are
acting within the scope of their employment.
The legal status of other non-regulated health personnel who are directly
involved in genetic laboratory testing is equally uncertain. 
Liability could become a greater concern in the future as predictive genetic
testing becomes more common and the role of genetic counsellors and other non-
regulated health personnel expands and gains importance. Genetic counsellors will
likely bear increasing responsibility for their role as communicators, and more
liability could be placed on them. As testing becomes more widespread, other non-
regulated health personnel could also see their responsibilities increase. 
The regulation of genetic counsellors and other personnel who are directly
involved in genetic testing is likely to become necessary. Regulation would: 
recognize the importance of the services provided by these professionals,
increase their profession’s status, and 
establish more rigorous norms with regard to qualification, responsibility and
liability. 
Genetic counsellors and other personnel who are directly involved in genetic
services should be covered by the Regulated Health Professions Act. This could be
achieved by including new professions in the list of “Self Governing Health
Professions” in Schedule 1 of the Regulated Health Professions Act or by including
non-regulated personnel into existing Self Governing Health Professions.
Clinical Issues
Genetic testing raises specific issues about: 
n informed consent, 
n patient confidentiality, and
n the testing of minors and incapable persons.
Informed Consent
In Ontario, consent to health care treatment may be express or implied, verbal or
written. In general, implied consent is reserved for common, simple, low-risk
interventions in which the benefits greatly outweigh the risks. In the context of
genetic testing, express consent is required, due to the complexity of the
information obtained and its uncertain risk-benefit ratio.
The consent must also be voluntary, relate to the proposed treatment and be
adequately informed. This means providing a patient with the information necessary
to understand the purpose and implications of a proposed test, and to make a choice
based on his or her values. 
34 Genetic Services in Ontario: Mapping the Future
Given the complexity of the information that the patient must receive, the
possible consequences of undergoing testing, the probabilistic nature of the results,
and the uncertain risk-benefit ratio, some bodies recommend that consent to testing
should be written. This would further confirm the voluntary nature of genetic
testing and the right of the individual to withdraw his or her consent. 
The committee did not reach consensus on how to address this issue. The legal
and ethical issues sub-committee recommended that informed consent be written.
Other members of the committee expressed concern about the implications of a
written consent requirement for current clinical practice. The legal and ethical issues
sub-committee therefore recommends that the issue of written consent be further
reviewed. It encourages consultation with lay organizations who have drafted model
informed consent forms for genetic testing (e.g. The International Huntington
Association). 
Technological advancements also raise particular concerns about informed
consent. For example, multiplex testing such as microarray allows testing of a single
biological sample for multiple genetic disorders simultaneously. The potential cost
savings and the apparent efficiency of this technique make it an attractive option.
Because multiplex testing potentially involves testing for hundreds of conditions and
diseases at once, each significantly different from the others, it poses a particular
challenge for informed consent.
The basis of informed consent is that the patient receives and understands
enough information about the testing process and the condition being tested for, to
make an informed decision about whether to undergo testing. With multiplex
testing, this decision would involve hundreds of conditions. Should informed
consent be required for each test in a microarray panel, or would a generic consent
to all tests included be sufficient? 
Requiring health professionals to discuss each condition in advance of testing
would entail practical difficulties. This could be problematic in the current context
of limited resources. A generic consent would likely not be considered adequately
informed and would undermine the concept of informed consent and respect for
autonomy.
Various approaches could be taken to address these issues. The use of multiplex
testing could be strictly limited to exceptional situations in which important health
reasons can justify using this technology. If multiplex testing were deemed necessary,
tests could be grouped on different panels by related types of disorders, such as
those with similar availability of effective treatment, or similar severity or nature of
condition. This could make obtaining informed consent for each condition
manageable. 
If a Provincial Advisory Committee on Genetics is re-established, the committee
should follow technological developments in this area and continue to investigate
this issue. At this stage, there is no clear situation where multiplex testing seems
appropriate. 
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Testing of Minors
It is expected that in the coming years, the most frequent form of genetic testing
will be newborn screening. Newborn screening programs are generally used to
detect diseases that are treatable but would not be detected by simple physical
examination before their effects have manifested and become irreversible. 
To be included in a universal screening program, a disease should have the
following characteristics: 
n the disease will result in severe morbidity (mental and physical) and/or
mortality if it is not diagnosed in the neonatal period;
n clinical screening by simple physical examination is not effective and will not
identify the disease;
n an effective treatment is available; 
n there is a significantly improved prognosis with early treatment; 
n the disease has a relatively high incidence (greater than 1 in 15,000 infants); and
n there is a simple, rapid, reliable, inexpensive screening test.
Some jurisdictions have introduced mandatory screening programs under which no
parental consent is required. In these cases, the benefits of testing are considered to
strongly outweigh the possible risks. 
In Ontario, parental consent is required for any form of genetic testing or
screening of children and newborns. There are currently no exceptions to the
requirement for informed consent for newborn screening. 
The new Provincial Advisory Committee on Genetics, if appointed, should
examine how newborn screening is currently being conducted and whether health
care providers and parents are correctly informed about this issue. This research
should examine if there is a need for further education about the current ethical and
legal standards in this area and for changes to the system of newborn screening. 
The practice in Ontario of banking samples obtained from newborn screening,
and the process of informed consent for banking and the future use of samples,
require further review. 
Genetic testing of children raises serious ethical issues when the proposed tests
are not likely to provide timely medical or psychosocial benefits, or when the
benefits of testing will not accrue until adulthood, as in the case of adult-onset
disorders. Such testing could cause serious psychological harm, could expose
children to stigmatization and discrimination, and could deny their future
autonomy. 
For these reasons, the sub-committee recommends that newborns and children
should not be tested for genetic conditions where there are no timely medical or
psychosocial benefits, or where these benefits will not accrue until adulthood. 
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Confidentiality 
A patient’s genetic test results generally reveal information about the risk status of
family members. If the patient’s results are relevant to family members, the patient
should be encouraged to share that information with them. If the patient refuses to
share this information with them, should the physician breach confidentiality to the
patient in order to inform the family members that they are at increased risk of
developing a particular genetic disorder? Doing so could damage the patient’s trust
in the physician but if the disorder is preventable or treatable, it could have a
significant impact on the health of family members. 
Further research should be undertaken to determine whether disclosing genetic
information to high-risk relatives against an individual’s wishes should be allowed.
Any criteria to allow this disclosure should include the following conditions: 
n the interest in informing relatives strongly outweighs the interest in maintaining
confidentiality;
n reasonable attempts to elicit voluntary disclosure are unsuccessful;
n there is a high probability of serious and irreparable harm to an identifiable
person;
n the disclosure of the information will enable that person to prevent the harm,
and there is a high probability that the harm will occur if the information is
withheld; and
n the disclosure is limited to the information necessary for the diagnosis or
treatment of the third party
Storing Genetic Information and Genetic Material and 
Protecting Privacy
Because DNA samples and genetic information have the potential to be stored
indefinitely, special consideration needs to be given to issues of:
n ownership of samples and test results, 
n consent to storage, 
n time limits for storage, 
n use of samples in research, 
n recall of tested individuals, and
n privacy and confidentiality of patient information. 
Stored genetic information and genetic material may be of interest to third parties such
as family members, insurance companies and employers. Legislation is needed to:
n protect the privacy of all health information including genetic information, 
n establish norms for the collection and storage of such information, and 
n determine who should have access to stored genetic information and genetic
samples under various circumstances. 
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Report of The Evaluation Sub-Committee
Objective 
n To develop an evaluation framework that would guide decision-makers’ and the
public’s priorities in making genetic predictive tests available through the
publicly funded health system. 
Findings
The Evaluation Sub-Committee proposes an evaluation framework for making
predictive genetic tests available through public financing. The Sub-Committee:
n defines the elements of decision-making, 
n makes recommendations about the structure of the evaluation process, and
n introduces an evaluation template to be used by evaluators34. (See Appendix F).
Because the use of innovative decision frameworks improves as decision-makers
learn about their utility through experience, the evaluation template is presented
as a starting point. 
Decision Framework for Genetic Testing
Predictive tests differ from diagnostic genetic tests by suggesting future rather than
present disease. The predictive power of these tests varies by disease and by test.
Tests for genetic diseases where mutation status implies the certainty of disease in
the future (e.g. Huntington Disease) have near-100% predictive power. Tests for
genetic diseases where mutation status creates an increased risk (susceptibility) of
disease (e.g. BRCA1/2) have lower predictive power.
Like any new and evolving technology, predictive genetic tests can constitute a
major pressure on health services (Stevens35, Newhouse36) prompting policy-makers
to engage in priority setting and rational evaluations of effectiveness. In addition,
predictive genetic tests have some particular characteristics that warrant specialized
attention37.
To date, few evaluation frameworks for predictive genetic tests are available to
guide both technology assessment and priority setting. Large public policy agencies
have conducted most of the available evaluation efforts. They have concentrated on
evaluating technologies for their safety and effectiveness in order to secure approval
as marketable health products. These evaluations do not generally address questions
of service coverage and issues related to medical, personal or economic effectiveness. 
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34 Appendix E contains a list of papers produced for the Advisory Committee, including those
produced by the Sub-committee on Evaluation
35 Stevens, A, R Milne, R Lilford, and J Gabbay. 1999. Keeping pace with new technologies: 
systems needed to identify and evaluate them. British Medical Journal 319:1291.
36 Newhouse J P. 1992. Medical care costs: how much welfare loss? Journal of Economic 
Perspectives 6 (3): 3-21.
37 For a fuller discussion, see the Sub-committee Discussion Paper 7.5, listed in Appendix E
In Ontario however, evaluation frameworks must grapple with a full spectrum of
evaluation criteria38. 
The sub-committee proposes an evaluation framework for making predictive
genetic tests available through public financing. The framework:
n proposes criteria for these evaluations, 
n defines the elements of decision-making, 
n makes recommendations about the structure of the evaluation process, and
n introduces an evaluation template39. 
Any evaluation process should include a rigorous analysis of the evidence and
respond to the social and cultural context in which the evidence is being interpreted
and applied. 
Many factors will enter into funding decisions about predictive genetic
technologies, including clinical and economic issues, and the opportunity and
magnitude for benefit and harm that can result from the service. Because different
interests will weigh factors differently, evaluation must include input from a variety
of stakeholder and expert groups, and ensure that the process remains flexible. 
Evaluating Predictive Genetic Technologies
In a recent talk, Dr. Ed McCabe, Chair of the U.S. Secretary’s Advisory Committee
on Genetic Testing (SACGT), raised the issue of “an unresolved dichotomy”
between the role of the Food and Drug Administration (FDA) in reviewing the
safety and effectiveness of genetic tests and the role of the Centers for Medicare &
Medicaid Services (CMS) in determining which tests are necessary and reasonable,
and therefore warrant public coverage40. 
This dichotomy is apparent in Canada where the federal government makes
decisions about the approval of new health products but provincial governments are
responsible for providing public coverage for necessary and appropriate medical
services. 
To date, most efforts to develop systematic criteria for evaluating genetic tests
have focused on issues relevant to federal review, rather than provincial resource
allocation41. Exceptions include current initiatives in the UK that address the
National Health Service provision of genetic services, and the sophisticated model
developed by the Crossroads 99 group42. Both are incomplete. 
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39 Appendix F contains the proposed evaluation template produced by the Evaluation Committee.
40 Dr. Ed McCabe, 2001
41 See the background paper of this title by Fiona Miller, Ph.D. and Mita Giacomini, Ph.D. both of the
Centre for Health Economics and Policy Analysis and Department of Clinical Epidemiology and
Biostatistics, McMaster University, 7.4 of the Subcommittee on Evaluation.
42Goel, V (for Crossroads 99 Group), Appraising organised screening programmes for testing for
genetic susceptibility to cancer. British Medical Journal 322:1174-1178 (2001)
In the absence of developed models, the Evaluation Sub-Committee developed a
new approach to the evaluation of predictive genetic tests. It is informed by the
work of other groups including the SACGT.
Guiding Assumptions 
The evaluation of predictive genetic technologies as a health service should consider
more than simply the technology itself.
Unit of Analysis
The sub-committee adopted as the unit of analysis, the genetic test service – a
package of three elements: test technology, target population, and clinical condition.
Each of these elements must be specified and must be taken together for the
evaluation and coverage decision to be meaningful.
Multiple Criteria
The evaluation of predictive genetic tests must take many criteria into consideration,
including:
n technical accuracy (analytical validity), 
n clinical effectiveness (clinical validity), 
n usefulness to tested individuals (clinical utility), 
n adverse and additional effects, and
n expansion potential and cost (social utility). 
Many of these criteria are not traditionally considered by the clinical evaluative
sciences. Adequate assessment of these criteria may require the use of different
forms of expertise and evidence, including quantitative studies, case studies and
other types of qualitative research designs.
Complex Decision Sequence
The multiple criteria to be considered in the evaluation of predictive genetic tests
are not amenable to a linear, hierarchical decision process where criterion A is met
before criterion B is considered. While some decision criteria can be determined in a
linear and hierarchical fashion (e.g. technical accuracy), many other criteria must be
assessed as a whole.
Jagged Cutoffs and Grey Zones
Many criteria for assessing predictive genetic tests have poorly defined cutoffs or
cutoffs may differ for different circumstances. There is limited evidence to support
decision-making in particular cases. The recommended approach explicitly
recognizes these jagged cutoffs and grey zones.
Jagged cutoffs are value-laden criteria for deciding what is “good enough” in any
given category for a particular circumstance. Establishing the cutoffs requires
answering questions such as “How worthwhile is worthwhile enough?” and “How
effective is effective enough?”
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Grey zones are indeterminate evaluations. Although cutoffs have been
established, it is not clear where a particular test should fall because of uncertainty
or a lack of information. If a case falls in the grey zone, conditions on practice
(e.g. practice guidelines, regulation of practice, priority setting, pilot studies, phased
introduction, etc.) are required to supplement “yes/no” coverage decisions. The
“Grey Zones” concept is illustrated on page 54.
Assessing Analytical and Clinical Validity of Genetic Predictive 
Technologies and Systematic Review Methods
For a clinical diagnostic or predictive test, validity refers to the extent to which the
test measures what it is intended to measure. The analytical validity of a genetic test
refers to the ability of the test to accurately measure the gene/mutation or gene
product of interest in the laboratory. 
Accuracy is a function of the sensitivity of the test (its ability to detect the
gene/mutation or product when it is present), and its specificity (the ability of a
negative test to correctly identify an unaffected individual). These parameters define
the performance of the test in the laboratory, and are routinely assessed as part of
usual laboratory quality control programs. These programs also specify the
conditions under which the test is performed, and the reliability of the estimates. 
A more complex assessment of a test’s performance is its clinical validity. Clinical
validity of a predictive test is assessed according to its ability to correctly predict the
clinical condition of interest based on the test result. Like analytical validity, the
clinical validity of a test can also be defined in terms of the test’s performance in
correctly predicting a future clinical condition when the condition is destined to
occur (sensitivity), and correctly predicting that the condition will not occur
(specificity). The clinical accuracy of the test is a function of its sensitivity and
specificity. 
But, for genetic predictive tests, clinical sensitivity and specificity are rarely
useful performance measures because of the low predictive power of these tests in
many conditions. 
For conditions where a positive test will almost always be associated with the
development of a clinical condition (e.g. Huntington’s Disease), sensitivity and
specificity are useful concepts to describe clinical validity. But, where a test is
predicting, for example, the risk of disease compared to a control group, or an
absolute risk for the individual with a positive test compared to more people with a
positive test likely not to develop the disease (low predictive power), sensitivity and
specificity become less meaningful as performance measures of the test. In these
cases, clinical validity is evaluated according to how close the claims for the
predictive power of the test come to actually predicting the risk of the condition
occurring. 
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To assess the validity and precision of such clinical risk estimates, evaluators
must examine the quality of the evidence upon which such claims are made, and the
specific circumstances under which the data were generated. Criteria do exist to
help evaluators determine the quality of the evidence upon which validity claims of
this type are made43.
In examining the data that supports claims for analytical or clinical validity,
evaluators should ensure that the studies used are not based on a biased sampling of
the literature and that the populations from which the estimates are made are
relevant to those who will be considered eligible to receive the service. Evaluators
must understand the generalizability of a test’s performance from one population to
another. They should also undertake a comprehensive sampling of the relevant
literature and be aware of publication bias that can provide optimistic assessments of
the performance of genetic predictive tests. 
Elements of Decision-Making – Explaining the Evaluation Template
The main decisions required are whether a particular genetic predictive test or
service warrants approval for public financing and under what conditions. Two sub-
decisions are relevant: 
n the appropriateness of making a predictive genetic testing service available in a
particular case, and 
n the specific genetic technology that should be used to detect the
gene(s)/mutations in question.
The proposed evaluation template (see Appendix F) addresses seven main decision
steps. 
1. Does the intended purpose of this service justify continuing with the evaluation?
The intended purpose should be stated clearly by individuals or groups who
recommend the service before an evaluation is permitted to proceed. The purpose
must apply to the fully-defined service comprising the technology, the target
population and the clinical condition.
This first decision step asks the evaluators to determine whether the intended
purpose justifies continuing with the evaluation. In effect, the evaluators are asked
to make a value judgement about how compelling or non-compelling the intended
purpose is from the perspective of the individual who will be tested, or society as a
whole, irrespective of whether the purpose can be achieved technically. 
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2. Does the performance of the test in the laboratory justify further evaluation?
The analytical validity establishes whether the test measures or detects what it is
intended to measure, and includes consideration of the reliability of the
measurement of the test. Evaluators will want to assess the adequacy of available
evidence for validity and reliability. This criterion is measured by the laboratory
performance of the test as expressed through sensitivity, specificity and accuracy and
is part of usual laboratory quality control processes.
3. Does the clinical performance of the test justify further evaluation?
Clinical validity ascertains:
n how accurately the test predicts the probability/occurrence of a future clinical
state for a specified circumstance, 
n reliability of the test. Technically, this is assessed differently but is related to
validity, and 
n the adequacy of available evidence upon which the clinical test performance
data are based. 
4. Considering alternatives to the proposed service. 
The availability of alternatives determines how the proposed test compares with
other resources for the same or similar predictive purposes. Evaluators should assess
whether the proposed test will complement, replace or be replaced by alternatives
and what additional information the proposed test provides. 
Often, the proper evaluation of a particular test or service requires that it be
evaluated in the context of a cluster of other complementary tests, frequently according
to a prescribed sequence. Evaluators will need to determine where in the sequence of
tests the one being evaluated belongs to achieve optimal effectiveness and efficiency.
5. Expected outcomes of service use.
This step examines what clinicians and individuals can do with the test results. For
example, will the test result alter the clinical (medical, psychosocial) management of
the tested individual? How will the test result prove useful to tested individuals for
personal or family management? 
Evaluators are asked to determine any potentially negative outcomes, such as for
clinical management or labelling effects for tested individuals and family members.
Labelling effects refer to unanticipated health consequences that can be triggered
when otherwise healthy people are given a diagnosis of disease, irrespective of
whether the disease itself causes symptoms. There might also be unanticipated or
secondary positive outcomes, such as reduced utilization of health services for those
with a negative test that is confirmed not to be associated with increased
susceptibility to disease. 
Relevant information will come primarily from clinical trials and other studies of
effectiveness. 
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6. Are the known and potential additional effects of the proposed service acceptable?
Additional effects extend beyond expected or intended outcomes for the tested
individual to other individuals, including the family and the community. Labelling
effects and stigmatization of the individual or family members might also apply here. 
Clinical, personal, social and cultural effects need to be determined. Social
effects may be described as legal, ethical, and economic. Once additional effects of
interest are identified, evaluative research (i.e. studies of effectiveness) can offer
information about the magnitude and causes of these effects. 
7. Are the known and potential costs of providing the proposed service acceptable? 
Data on the economic implications of predictive genetic tests are hard to develop
and are often not readily available. Discussion Document 7.3 listed in Appendix E
outlines the principles for conducting cost effectiveness evaluations of emerging
predictive genetic tests. 
Often economic evaluations are restricted to the direct costs of the test or
service. Direct costs refer to the immediate funding required to provide the service
and include unit price and projected service volumes. These reflect the test
algorithm used, human resource, operational and capital costs44.
Using only direct costs can give a false impression of the true economic
consequences of introducing a test or service. Such evaluations should include an
estimation of indirect costs. For example, a test or service that has high acquisition
or infrastructure costs may offset other higher costs later on, if disease or intensive
investigations can be avoided because of the test. 
Indirect costs can also include such things as lost wages resulting from a test
service or the disease for which it predicts, which can then affect taxation revenues
and reduce productivity. For example, labelling effects have been shown to lead to
increased absenteeism from work where people were falsely diagnosed (i.e. labelled)
with hypertension. 
Ultimately, both unit cost and demand affect the cost of providing a genetic
service. The demand depends upon the prevalence of the associated disease and the
likely population of candidates who will use the service.
Expansion potential is the likelihood that the genetic service may, in time,
become redefined in the course of clinical practice or product marketing to include
broader populations, clinical contexts or indications. This will be determined not
only by the prevalence of associated diseases, but also by popular beliefs about the
relevance of information about risk status, and the availability of product marketing.
Expansion potential could be initiated immediately, or over a period of time. The
potential economic consequences of an expanded service should be considered45.
44 Genetic Services in Ontario: Mapping the Future
44 See Discussion Document 7.3
45 See But What Will They Really Cost? Economic Considerations for The Public Funding of Emerging
Genetic Tests, Decision document 7.3 of the Sub-committee Report.
Further decision steps occur within each of these seven steps. The decision to
continue with the evaluation may be made with certainty, or it may be uncertain –
lying within a grey zone (see figure 1). In either case, the final decision about
whether or not to recommend a potential predictive genetic service for provincial
coverage will await the results from each step of the evaluation. 
Where the decision falls in a grey zone, there are likely to be conditions
attached, such as the requirement for more research, limited introduction, or the
need for clinical or ethical protocols to guard against certain adverse or additional
effects.
Evaluators and policy-makers will have to develop the cutoffs for each decision
as they proceed and this task should be tackled explicitly.
Because the use of innovative decision frameworks improves as decision-makers
learn about their utility through experience, the Evaluation Sub-Committee presents
the Evaluation Template as a starting point.
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Examples of Analytical Questions for Defining the Cutoffs 
for Evaluative Criteria
What constitutes a worthwhile purpose for a new health service?
n Are alleviation of anxiety, reduction of uncertainty, clarification of paternity,
information for family or life planning, worthwhile goals in themselves? Should
they be valued strictly in terms of their longevity or quality of life effects?
n Is generating intermediate clinical or biological information worthwhile in itself,
or must testing results play a definitive role in diagnosis or treatment?
n If reduction of uncertainty is a worthwhile goal, how much must a test reduce
uncertainty to make it worthwhile?
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Conditions on 
funding coverage
Evaluation criteria Assessment of this test (if in grey cells)
Intended purpose Worthwhile Not worthwhile Unclear Clarify before further 
evaluation.
Effectiveness Effective Ineffective Unknown Research protocols.
Additional effects Acceptable Unacceptable Worrisome Interventions, additional 
or unknown effects. 
Ethical protocols?
Regulation? 
Research protocols? 
Clinical practice protocols?
Unit price Low High Priority setting under 
defined envelope.
Expected demand Low High Priority setting under 
defined envelope.
Expansion potential Low High Clinical practice protocols.
Priority setting under 
defined envelope.
Periodic re-evaluation.
Jagged Cutoffs 
Figure 1
Grey Areas in the Evaluation and Coverage of Genetic Testing Services 
The General Model 46
46 See Section 5.0 of the Evaluation Committee Report
n If life saving is a worthwhile goal, how much life should be gained for a test to
be worthwhile?
n If quality of life improvement is a worthwhile goal, how much improvement
would be worthwhile, and according to what scale?
What would constitute an effective health service?
n What would constitute scientifically adequate evidence of effectiveness? 
n How should effects on others be measured and assessed?
n How should harms offset benefits in the calculation of effectiveness? Are there
any harms that would trump all benefits, or is the judgement entirely a question
of ratios and degrees (e.g. very harmful tests may be tolerated to achieve
significant gains in life)?
Which additional effects would be considered acceptable?
n Do genetic tests as a class present harms to societies or to groups within society? 
n Might certain genetic tests present any categorically unacceptable harms to
societies or communities?
n If the benefits and burdens introduced by the service are not distributed equally
through a population, what kinds of distributions would be inequitable?
What is an acceptable level of costs for providing a new service?
n Considering the interactions between unit price, demand, and the potential for
expanded demand after coverage, how expensive is too expensive for providing
any one service? 
What is an acceptable level of cost effectiveness for a new service? 
n How many units of effectiveness (e.g. life years gained) per dollar of cost are
required to qualify any new service as worth the investment of funds?
n What interests should determine the parameters of cost effectiveness estimation?
For example: time period (long-term, short-term), perspective (governmental,
societal), and outcomes (health, well-being).
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Defining the Characteristics of Predictive Genetic Tests: 
A Framework for Evaluation Decision-Making
The sub-committee developed a framework for analysing the characteristics of
predictive genetic tests that are relevant to the evaluation process. The approach
compares predictive genetic tests to two related health technologies (diagnostic
genetic tests and non-genetic predictive tests) across four dimensions, and also
distinguishes three types of predictive genetic tests. The analysis of predictive
genetic tests demonstrates three things: 
1. Predictive genetic tests share many characteristics with diagnostic genetic tests. For
example, both have characteristics with respect to the information they provide that
distinguishes them from other medical tests. Molecular genetic tests permit more
information to be gleaned from more kinds of biological samples, and much of this
information has relevance for individuals other than the one tested, including future
generations.
There are other characteristics shared by predictive and diagnostic genetic tests
that are less obvious. In particular, there is the high potential for the commercially
driven expansion of these health services. This can create challenges for policy-
makers with respect to timely and efficient technology assessment, and the need for
an effective gatekeeping function.
Predictive genetic tests also share important characteristics with other medical
tests, specifically non-genetic predictive, or screening tests. Both types of predictive
tests have the potential to create “protodiseases” – to generate disease states in
otherwise healthy but at risk individuals. 
The recognition of this parallel should encourage policy-makers to draw on the
accumulated knowledge of the merits and demerits of disease screening programs
when developing new programs for predictive genetic tests. Many of the evaluation
criteria that are relevant to disease screening are also relevant to predictive genetic
testing
2. Despite the existence of shared characteristics, the analysis demonstrates that
predictive genetic tests have a unique characteristic of “disease malleability.” This refers
to the complex relationship between diseases and genetic status. It can be difficult to
attribute certain disease states to single mutations and mutations may manifest to
produce more than a single state disease. Traditional ways of organizing and
evaluating disease screening or diagnostic testing do not accommodate this unique
situation.
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3. Predictive genetic tests can be distinguished by three types – presymptomatic, familial
susceptibility, and risk-factor. These analytic distinctions have policy relevance for
assessing the utility of testing programs (see Table below). 
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Predictive Diagnostic Non-Genetic
Genetic Tests Genetic Tests Predictive Tests
Technical Scope Test Capacity n Enhanced n Enhanced n Standard 
Significance n High n High n Low
for biological n Moderate
family members
Clinical Impact Utility n Medical n Medical n Medical
n Information
Additional Effects Creating n Yes n No n Yes
proto-disease
(identifying the 
potentially-ill 
well
Expansion Potential Opportunity for n High n High n High 
commercial
exploitation
Disease Malleability Clarity and n High n High n Low
consistency of 
disease identity
A Comparison of Genetic and Predictive Test Technologies
Recommendations
The Evaluation Template and accompanying Toolkit developed by the sub-
committee be adopted as the basis for the evaluation of new predictive genetic
services in Ontario. 
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Presymptomatic Familial Susceptibility Non-Genetic
Predictive Genetic Tests Predictive Genetic Tests Predictive Tests
Disease n Rare genetic n Less rare diseases n Common or relatively 
diseases (often hereditary forms common conditions
of common conditions)
Genetic Involvement n Single gene disease n Single gene has n Complex genetic 
n 100% penetrance major impact on disease causation
n Clear familial n Significant penetrance n Low penetrance
transmission n Familial transmission, n Non-obvious patterns 
but less clear because of familial transmission
of reduced penetrance
Predictive Power n Virtually all people n Many people testing n Most people testing 
testing positive will positive will never positive will never 
develop the disease develop the disease develop the disease
if they live long enough
Client Populations n Very small client n Small client population n Potentially relevant to 
population major impact on disease the population-at-large, 
n Family history provides n Family history provides or major sub-populations
a clear indication of a reasonable indication n Family history not 
the client population of the client population decisive in identifying 
n Pre-screening to identify n Pre-screening needed candidates
appropriate candidates to identify candidates
Practitioner n Genetics specialists n Disease specialists n Disease specialists 
n Primary care
Utility of Testing n Informational utility n Medical utility alone n Medical utility alone
alone or combined or combined with 
with medical utility informational utility
Three Provisional Types of Predictive Genetic Tests 47
47 From: Miller F and Giacomini M. Defining the characteristics of predictive genetic tests: A
framework for evaluation decision-making, Table 2. Evaluation Committee background paper 7.5.
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Report Of The Laboratory Sub-Committee
Objective
n To examine all issues on laboratory predictive genetic testing. This included:
n best practices, 
n the availability of trained personnel, 
n the number and type of training programs for laboratory personnel, and
n the ability to implement an effective quality assurance program. 
Findings
Three systemic laboratory issues are critical in designing a responsible lab system to
deal with genetic issues:
1. Genetics testing must be integrated into the existing lab medicine system as
much as possible. Every effort should be made to integrate genetic service into
the Ontario health care system and not to isolate genetic lab testing.
2. The use of similar technology in labs means that many tests can be used as
either a unique diagnostic test or to provide family information. Any system of
accountability must not interfere with providing a well functioning lab service
that also properly services the need of acute medical care. Genetic testing must
be integrated into existing general test review processes.
3. A systemic shortage of resources in laboratory services in Ontario must be
addressed as genetic-based technology expands in laboratories. 
The Need for Quality Assurance and Confidentiality
Ontario’s health care system is built on the confidential relationship between the
physician as the main provider of health care services and the patient as the
consumer of health care services. Tests and services requested by the physician are
an integral part of that relationship. 
To protect the integrity of the relationship, ensure patient confidentiality, and
minimize inaccurate test results, the three components of a genetic test – pre-test
preparation, laboratory analysis and interpretation and support consultation of test
results – must be integrated into clinical practice.
During the pre-test phase, physicians must have access to accurate information
to inform the patient about the test, the disease or condition under consideration,
and the benefits and risks associated with a genetic test. To maximize the value of
the informed consent process, the physician must have access to readily available
and reliable information about the genetic test. 
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The laboratory analysis must be valid, accurate, efficient and ethical. Neither the
patient nor the health care system can afford the emotional distress or financial
expense of inaccurate test results. At all times, care must be taken to protect patient
confidentiality.
The laboratory has become a useful resource for family physicians and other
health care providers by providing analysis and interpretation of test results and
support about referral for clinical management assistance and communication with
other family members. 
Quality Assurance 
Standards for lab services are established through professional societies and
regulated through the College of Physicians and Surgeons of Ontario and the
College of Medical Laboratory Technologists. In Ontario, the Quality Management
Program in Laboratory Services (QMPLS) monitors compliance with those
standards. 
All genetic tests performed in Ontario must be subject to a quality assurance
program that meets professional, technical and ethical standards. Standards for
genetic testing should include an informed consent process, full disclosure of
available options for the patient and the option of follow-up consultation. As with
all laboratory testing, an ongoing mechanism of consultation between the laboratory
and the health care provider who requested the tests should be established.
New Technologies
Laboratory testing in genetics is changing quickly. With the rapid evolution in our
knowledge of the genome and advances in “molecular” techniques, techniques in
genetics have swiftly expanded. Advances in the automation of several molecular
genetic techniques, such as sequencing, polymerase-chain reaction, and nucleic acid
extraction continue to emerge. 
Perhaps the most significant advance in molecular genetic testing will be achieved
through the use of microchip arrays of molecular probes. This technology will allow
for the fast, high volume screening of mutations within large genes, as well as the
simultaneous genetic typing of individuals for mutations in many different genes. 
It is likely that tests for multiple diseases may be done on a single specimen
sample, such as microarray testing for numerous genes or gene products, or multiple
tests on a newborn screening specimen as part of provincial screening initiatives.
Multiple tests on single samples add additional complexity to the informed consent
process and increase the difficulties in producing clear and understandable lab
reports.
No single methodology for performing genetic testing will be sufficient. To date,
the numbers of samples and diseases being analyzed in labs have been limited by
methodology and staff resources. 
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Despite its advances, molecular genetic testing is still in its infancy and will
require new types of equipment not present in today’s medical laboratories. The
system should also be prepared to handle a vastly increased workload in molecular
genetics. This will require investment in the new technologies to deal with the
volume and maintain the quality of genetic services.
Systemic Issues
A number of systemic issues impact on the operation of laboratory medicine in
Ontario including:
n shortages of trained personnel, 
n strong commercialization pressures, 
n the prospect of pharmacogenetic lab testing to individualize drug therapy to
patients, and 
n the use of laboratories in jurisdictions outside the province. 
It is critical that the new genomic technologies and these systemic laboratory issues
be addressed as part of the revitalizing and reorganizing of laboratory services in
Ontario. 
Staff Resources
There is a shortage of trained personnel at all levels in the field of genetics
including:
n laboratory physicians, 
n cytogeneticists, 
n molecular and biochemical geneticists, 
n technologists, and 
n technicians. 
While the lack of trained health personnel is not unique to genetics, the anticipated
growth in demand for genetic services compounds the problem. 
Evaluation of Future Therapies
In addition to laboratory-based diagnosis, there is the prospect of pharmacogenetic
drugs, protein/enzyme replacement therapy and gene therapy. 
All of these potential options will draw new, as yet undefined, lab technology and
services into health care. Each will require laboratory professionals to participate in
some components of the therapy. For example, the identification of the location and
type of mutations in a gene may dictate the type and efficacy of a particular gene
therapy that can be used in an individual case.
Measuring the effect of the new drugs and therapies used to treat genetic disease
will likely involve examining patient outcomes in relation to the results of the
genetic tests. The impact of these new treatment options needs to be reviewed before
they are introduced. With the potential development of these new services, coupling
of lab testing with clinical outcomes becomes a pressing need.
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Out-of-Province Testing
In some cases, the rarity of some genetic disorders requires that specimen samples
be sent out of the province. Meanwhile other jurisdictions will send specimens for
other rare tests to Ontario.
Consideration should be given to the development of a policy that permits the
use of laboratories in other jurisdictions. Since laboratories in Ontario are beginning
to function as part of a global system, they should comply with the rules and
regulations of other jurisdictions. The Province’s Quality Management Program in
Laboratory Services participates directly in international development of these
standards. 
Any testing done by an out-of-province laboratory must meet the professional,
technical and ethical standards established and monitored by Ontario’s QMP-LS.
Stakeholders 
Genetic testing has been performed in Ontario for many years in various settings,
including commercial laboratories, hospital laboratories, and physicians’ private
laboratories. Funded predictive genetic testing has only been carried out by hospital-
based genetics laboratories because of concerns about the need for a coordinated
system for Ontario residents. 
The Sub-Committee’s recommendation of standards for genetic tests begins to
formally address some of the concerns about the lack of a coordinated system of
genetic testing involving public and private facilities. 
Recommendations
Since the Laboratory Sub-Committee produced its final report, changes continue
to occur in the test review process currently being proposed for Ontario. This
transition has allowed the sub-committee to modify its original recommendations to
accommodate this apparent change in the Test Review Process. The original report
and the full recommendations should be read to fully review the issues in
laboratory genetics.
In light of these apparent changes, the Laboratory Sub-Committee offers
modified and abridged recommendations in the following areas: 
n Genetic testing should be coordinated as a program of medical services that
must address:
n the pre-test component, 
n the laboratory analysis component, and 
n the clinical outcome of the service.
n A prerequisite for an effective genetic testing program in the province is an
effective education process for all health care professionals who may order
these tests. 
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n All laboratories providing genetic test results need standard provincial genetic
testing requisition and agreement on nomenclature and report format.
n External quality assessment must monitor all genetic testing.
n Laboratories providing genetic test services must be linked in an effective way to
share information about rules and regulations for patient confidentiality.
n The current process for test introduction is in transition and needs to be
harmonized to provide an effective system for timely review of tests. Genetic
testing must be integrated into the general test review process, and not dealt
with separately and in isolation. This test review process should be well
publicized and open to review. Reasons for the rejection of a new genetic test
and the implications associated with this rejection must be transparent.
n All genetic tests linked to any identified patient must be processed according to
standard published provincial regulations.
n All laboratory professionals involved in patient testing should be subject to
regulatory control.
n The Royal College of Physicians and Surgeons should review the potential for
incorporating formal training in human genetics into specialty training programs
in laboratory medicine. The training programs for MD/PhD professionals and
laboratory technologists should be coordinated to provide uniform and
consistent training that facilitates communication between laboratory personnel
and the performance of laboratory functions. 
n There is need for support and funding for training site infrastructure. The
appropriate accredited training programs should be encouraged to develop a
coordinated training program for laboratory genetics staff in Ontario. 
n All personnel directly involved in genetic testing should be members of
regulated health professions.
n The Advisory Committee should establish a mechanism to monitor the
implementation of its report.
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Report Of The Clinical Sub-Committee
Objective 
n To develop a clinical framework for the referral, testing, counselling, treatment,
and follow-up of patients with genetic concerns, particularly in regard to new
predictive genetic tests. 
Findings
As knowledge of the genetics of common multifactorial disorders (e.g. heart disease)
increases, genetic issues will move further into the mainstream of medical care. All
health care providers will need the knowledge, framework and supports to deal with
these issues. 
The Clinical Sub-Committee’s report provides guidelines for how this can be
done. It also highlights issues of concern, where input from experts in education,
law, ethics, and psychosocial fields is essential.
Advances in genetic knowledge and technology are increasing the information
that physicians can provide to patients. The technology allows for the diagnosis of
some genetic disorders before the patient develops overt symptoms (predictive
genetic tests). It also allows for the identification of genetic mutations or variations
that may be risk factors for disease. These “susceptibility genes” can be added to
other known risk factors (e.g. diet, environment) when assessing and treating
patients. 
Predictive genetic tests deal with the chance that a disorder will develop in the
future. In many cases, the information derived from the test is useful to help prevent
or delay the onset of disease. It also facilitates the transition from presymptomatic to
affected status, even if there is no preventive measure possible. The information is
useful to patients and their families in life planning and reproductive choices.
Because of the complexity and ambiguity of the results of genetic testing, and its
tendency to heighten psychosocial problems, providers of genetic information will
require new ways of communicating potential risk to patients. Education for health
care providers and for the public is essential to help them understand the purpose and
limitations of the tests, and how the results can best be used to improve quality of life.
In the clinical context, legal and ethical issues constantly arise. These include
informed consent, patient confidentiality, testing of minors and incapable persons, as
well as issues involving reproductive choices. For example, if a patient refuses to
share genetic test results, should the family physician breach the duty of
confidentiality to inform family members that they are at risk of developing a
particular disorder? This could damage a patient’s trust in his or her physician, but
to the extent that the disease is preventable or treatable, it could have impact on the
health of family members. 
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These issues are described in detail in the Legal and Ethics Sub-Committee’s report. 
In Ontario, guidelines and education will assist in the proper utilization of
genetic tests and services. The availability of private commercial genetic testing in
other countries or jurisdictions is a concern. The downstream costs of privately
purchased, inappropriate genetic tests are difficult to assess, but would have an
impact on our health care system. Educating the public about genetics would help
with this issue.
Key Steps for Genetic Counselling and Testing
The components of genetic counselling and testing are the same whether provided
by a family physician, geneticist, or other specialist. Assessing the patient by history
and physical examination is part of standard medical care. Part of the assessment of
a genetics patient involves an analysis of the patient’s risk of developing a genetic
disease, and whether genetic testing may be of value. 
The process of genetic testing involves informed choice and consent. The
physician or genetic counsellor will review basic genetic principles, as well as
information about the disorder, details regarding the purpose and limitations of the
test, and the advantages and disadvantages of testing. The issues of possible
discrimination in employment and insurance, as well as the chance of uncovering
information about relatives need to be discussed explicitly. The alternatives to
testing should also be presented in detail.
The decision for testing remains with the patient. The patient may require time
for reflection and to review all the information.
If testing is undertaken, the physician should discuss when results will be
available, how they will be conveyed, and to whom. Issues of confidentiality, and the
possible need to inform relatives at risk should be discussed before the test. If
testing is declined, there will still be the need for surveillance and follow-up of the
at-risk individual.
Psychosocial assessment is an important part of the initial counselling for people
at risk for genetic conditions. Patients at risk of crisis need to be identified, and
referral to the appropriate support person made. Physicians also need to be aware of
the possible development of psychological stress at any time following genetic
testing.
In the future, genetic testing for multiple susceptibility genes for common
disorders will become available. Genetic tests of this kind may be part of a general
risk assessment for any patient, regardless of family history. It may be unreasonable
and inappropriate to expect the same degree of detailed counselling for each part of
such an assessment. The components of genetic counselling in these circumstances
will need to be worked out by health care providers and experts in other fields.
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A Multi-Disciplinary Response
Genetic services are often provided in a multi-disciplinary environment to address
multiple factors such as:
n the lack of certainty in risk assessment and test results, 
n the variety of treatment options, and 
n the complexity of disease management. 
This multi-disciplinary response may involve numerous professionals including
geneticists, genetic counsellors, laboratory physicians and technologists,
psychologists, social workers and other allied health professionals.
Gene testing varies in complexity, psychosocial impact, and treatment options.
The need for pre- and post-test counselling and determining who should provide
advice varies with each genetic test and each patient. In some cases, the entire genetic
service will be offered in the setting of primary health care. In other circumstances,
the patient will benefit from referral to a specialized centre.
Factors that influence where and how a genetic service is offered are:
n gene prevalence, 
n complexity of management, 
n certainty of risk assessment and test results, and 
n the urgency of the case.
Human Resource Shortage
There is a shortage of human resources in the area of genetics in particular, and in
medicine in general with:
n not enough trained laboratory technologists to perform necessary tests in a
timely manner; 
n not enough geneticists and genetic counsellors for the current clinical load,
n not enough psychologists and social workers with expertise in the special issues
relating to genetics and the ability to provide the necessary support for patients;
and 
n difficulty in accessing the necessary supports for follow-up of at-risk patients
(e.g. colonoscopy, mammogram) in a timely manner. 
A variety of institutions provide training and regulation of personnel in genetics.
Medical genetics is a recognized specialty of the Royal College of Physicians and
Surgeons of Canada. The Canadian College of Medical Genetics is involved in the
accreditation of training centres and the certification of laboratory scientists and
some physicians. Laboratory technologists receive training in cytogenetics and
molecular techniques at the Michener Institute.
Physicians, nurses, and technologists are regulated by their colleges. Laboratory
scientists and genetic counsellors are not members of a regulated health profession
but work in a regulated environment. 
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Recommendations
The Clinical Sub-Committee’s recommendations are based on the assumption that
the genetic test or service offered has clinical validity and utility.
Access to Care
All patients are entitled to genetic counselling if they have concerns about their
genetic risks, even if they do not meet criteria for genetic testing. The counselling
will help to educate patients about their risks, with the aim of decreasing anxiety,
and avoiding the misuse of inappropriate genetic testing. 
People at increased risk for developing a disease may be offered additional
surveillance tests, or may need support to effect a lifestyle change. The expected
downstream impact of new genetic services should be reviewed at the outset. The
necessary supports and downstream services must be identified and in place before a
genetic test is made available. 
Equivalent services should be available across the province. Innovative ways of
delivering services may be needed, such as telemedicine and web-based resources. 
Quality Assurance and Outcome Evaluation
There should be a quality assurance system for all aspects of genetic services, not
just for laboratories. A provincial organization such as QMPLS could provide the
quality assurance program.
Outcome analysis should be part of the genetic service. The impact of the
service on patients, their families, and the community, in terms of disease prevented,
quality of life, and overall acceptance of the program should be evaluated.
All personnel involved in genetics should become members of a regulated health
profession even though this is a lengthy process.
Categories of Disease/Service
A categorization of disease should be used to assist in planning for the
implementation of new genetic services. This would help determine resource needs
and funding requirements. The categories are based on who will provide the pre- and
post-test counselling, and test interpretation. It is not intended that any family
physician or specialist be excluded or restricted from performing any genetic service.
Category 1: Disorders for which the majority of counselling and testing will be
carried out by the primary care physician or other specialists. These would
include common disorders for which there is straightforward testing (e.g. factor
V leiden). If the testing is straightforward for a rare disorder, the primary care
physician may choose to provide the counselling, or make a referral to the
genetics centre. 
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Category 2: Disorders for which selection of patients and pre-test counselling
are straightforward but interpretation of results is complex (e.g. cystic fibrosis).
The primary care physician or specialist would identify the risk, provide the pre-
test counselling and initiate testing. The genetic centre would provide
interpretation of the results and post-test counselling (e.g.cystic fibrosis).
Category 3: Rare disorders or conditions of such complexity that the best care is
provided through a multi-disciplinary program offered by a genetic centre with
appropriate referrals for prevention and/or surveillance. The primary care
physician or specialist would identify the possible genetic risk (e.g. breast
cancer, Huntington Disease).
Additional Recommendations
The Clinical Sub-Committee also offered recommendations in the following areas: 
Development of Guidelines for Facilitating:
n mechanisms for referrals
n the flow of information to the extended family
n access to testing
n access to additional services such as psychosocial support and counselling
n management of people changing from at risk to affected status.
Guidelines for Service Standards and Requirements:
n referral waiting time
n personnel at a genetics clinic/centre
n what should occur at a genetic appointment
n aspects of the laboratory test 
n communications with patient and with other professionals 
n accessibility and time to contact
n storage of genetic records 
n outcome measures for predictive testing.
Pre- and Post-Test/Counselling and Patient Follow-Up.
Regulatory Requirements for: 
n genetic counsellors
n out-of-province laboratories
n laboratories/clinics
n release of genetic information.
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Report Of The Psychosocial Sub-Committee
Objectives
n To identify the needs for psychosocial counselling in an integrated genetic service.
n To develop strategies for addressing the psychosocial implications of genetic
testing on patients and family members.
n To develop recommendations for screening people at risk who require
psychosocial counselling including managing people changing from at risk to
affected status. 
Findings
Psychosocial Impact on the Patient and Family
The diagnosis of any disease can cause anxiety. Knowledge resulting from new and
evolving genetic information has the potential to provide many benefits, but it can
also increase emotional distress, increase misperceptions of illness, lead to
stigmatization and other negative health outcomes. 
Genetic knowledge does not translate directly into desired health behaviour
changes. Psychosocial, emotional, and family factors play an important role in the
understanding of genetic information, health behaviour change, under or over
utilization of the health care system, and quality of life. 
The diagnosis of genetic disease has a number of unique risks because of its
complexity, ambiguity and tendency to heighten the psychosocial problems associated
with effective disease treatment, family relationships and adjustments to quality of life. 
While the results of genetic tests can be explained rationally, genetic information
deals with probabilities and doubts that can evoke irrational thoughts, images and
expectations for patients. It forces people to face their mortality, as well as raising
concerns about their children’s future. These concerns can be unsettling, so careful
attention needs be paid to the psychosocial impact of the technology on the patient.
Simply being informed about a genetic disease does not mean that individuals
will seek treatment or adhere to a treatment regime. People’s perceptions about the
new technology can influence their attitude about seeking a physician’s help or
complying with their advice. Efforts to persuade someone to accept a prevention,
surveillance or treatment strategy may go unheeded if that person is not motivated
to change behaviour. 
In many cases, no treatment options will be available. Patients may perceive that
if there is no cure, the disease is uncontrollable and threatening. This may result in a
sense of fatalism undermining their motivation to address the issue. 
The way people deal with genetic information is influenced by a variety of
psychosocial factors. First is a person’s perception of the risk. People who feel
particularly vulnerable to disease tend to overestimate the risk. For example, women
who have had a relative diagnosed with breast cancer and who may not be at high
risk for developing breast cancer but feel that they are at very high risk. 
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They may not be reassured by a negative test result and may adopt a denial
coping strategy that keeps them from either seeking treatment or complying with a
treatment regime. These women require educational counselling services that
include methods to address their worry about their cancer risk and gain optimal
understanding. 
Studies have shown that while perceived risk and anxiety play an important role
in an individual’s willingness to undergo testing, excessive anxiety can affect a
person’s:
n willingness to be screened, 
n adherence to surveillance programs, 
n adoption of lifestyle changes, and 
n willingness to seek additional information or services to alleviate concerns
about risk. 
Other factors that impact on patients’ reactions include: 
n pre-morbid psychological conditions, 
n perception of the illness as having few or no treatments,
n nature of the disease and associated stigma, 
n loss in the family,
n recent diagnosis in the family, 
n coping style, 
n perceived social support, 
n age, 
n gender, 
n socio-economic status, 
n culture, and 
n pre-test expectations. 
Impact on Decision-Making Ability
The knowledge of genetic risk can have a lasting and lifelong effect on the ability of
individuals and families to make future health decisions. Many people who test
positive for genetic diseases experience a reduced sense of control and feelings of
isolation, particularly when confronted by other unanticipated decisions after
receiving their test result. 
Any test result that brings forward serious and difficult decisions, can pose a
psychological burden that may limit a person’s ability to make decisions about:
n prevention and treatment options, 
n notifying extended family members and offspring, and 
n relationship issues involving marriage and children. 
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For example, women who test positive to the BRCA1/2 mutation, which is
associated with a higher risk of ovarian as well as breast cancer, are confronted with
the grim decision of surgery to remove their breasts or ovaries. They may also
struggle with the dilemma of whether or not to have children “knowing” they may
pass their genetic mutation on to them. It may also interfere with family
relationships and even radically change their perception and attitude toward
themselves and life generally.
Familial Threat
Another unique aspect of genetic diseases is that they pose a threat to both the
individual and family members. This can arouse not only fears about developing the
disease, but feelings of anger towards those who transmitted the disease, as well as
guilt or worry about potentially transmitting the genes to children48 49. 
Such emotional reactions have the potential to influence a person’s well-being
and relationships with other family members. These dynamics could also interfere
with the process of notifying family members who may be at risk of the disease and
require treatment.
While genetic counsellors may be equipped to deal with individuals who have
typical concerns, some individuals and families will require more specialized help to
deal with:
n difficult decisions, 
n family dynamic challenges, or
n serious psychological concerns, such as guilt about transmitting a risk to
offpsring.
Studies indicate that about 20-25% of people undergoing genetic testing experience
anxiety or depression levels requiring additional psychological services. Identifying
these individuals early in the process of genetic testing allows the genetics health
care provider to plan ahead for potential difficulties in their adjustment at later
stages.
Many individuals will not suffer from a psychiatric disorder, but will have a variety
of thoughts, feelings and behaviours that need to be understood in the context of a
person’s history. These individuals are often described as the “worried well”. They tend
to experience better adjustment to a test result if they have the opportunity to have
psychosocial counselling in conjunction with the genetic testing process. 
In order to provide psychosocial counselling to individuals undergoing genetic
testing, it will be important for providers to have skill and knowledge in identifying
individuals who may be at psychological risk.
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Although genetic testing creates anxiety and distress for some individuals, others
perceive the benefits of testing. In general, individuals who perceive more benefits
associated with genetic testing are more likely to want the test. The types of benefits
vary among diseases but may include the ability to use risk information to make
decisions on:
n career choices, 
n plans for retirement, 
n life insurance, 
n relationships, 
n treatment options, and 
n lifestyle.
Resource Implications
The Psychosocial Sub-Committee conducted a survey on eight regions in Ontario to
determine the level of psychosocial service in current genetic services. 
The most consistent concerns about the psychosocial impact associated with
genetic testing were that: 
n genetic counsellors/geneticists believed they needed further education and skill
in identifying those at psychological risk, and 
n when psychosocial issues were identified, there was no, or limited, access to a
mental health professional in their area. 
This finding was reported both in rural and urban settings. 
The committee identified the needs for psychosocial counselling in an integrated
genetic service. Currently, there is great variability in integrating mental health
personnel into genetic service teams. Often in developing new health services, the
psychosocial component is considered separate to the service. Prior experience and
the literature suggest that a bio-psychosocial model that integrates a psychosocial
component as an integral part of the service will best serve to identify those at
particular psychological risk, lead to the opportunity to address the psychosocial
impact, and result in more optimal health outcomes. 
Integrating a psychosocial component can potentially reduce health care costs. It
is frequently unaddressed psychosocial concerns or worry that result in patterns of
unnecessary or inappropriate use of health care treatments or surveillance measures
to alleviate concern or worries. Studies indicate that by proactively addressing
psychosocial issues early on in the testing process, the potential for harm and
further psychological or behavioural difficulties can be decreased.
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Current general mental health services in Ontario are stretched beyond capacity.
The development of any further medical service requiring psychosocial support will
need to carefully consider resource implications. The unique features of genetic
knowledge, its potential impact on the family, and the limited capacity for the current
mental health resources to address the psychosocial needs of emerging populations
undergoing genetic testing, suggest that careful planning will be required. 
Given the current limitations on mental health resources in Ontario, innovative
models of mental health care provision, such as the “ Shared Care Model “ (3)50, as
well as new funding paradigms may be needed to ensure that mental health
personnel and resources will be available.
Recommendations
The Psychosocial Sub-Committee recommends:
n integration of psychosocial and emotional support services into genetics service; 
n mandatory access throughout the province;
n ongoing quality assurance to ensure adequacy and access to psychosocial
services;
n commitment of resources for psychosocial services;
n commitment to training and support of health care professionals;
n commitment of funds for psychosocial services.
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Report Of The Education Sub-Committee
Objectives
n To review educational methods currently available provincially, nationally and
internationally.
n To develop recommended approaches to public, patient and provider education
requirements.
Findings
Health care is changing rapidly as a result of new advances in our knowledge of
genetics. The issue facing society and the health care professions is how to integrate
new genetic information and testing into health care practice. As the public’s
knowledge and need for information regarding genetics and genetic testing will
inevitably accelerate, it is essential to develop programs appropriate for a smooth
and efficient integration of this field into the health care mainstream.
The introduction of predictive genetic technologies requires the public and
health care providers to interact and communicate more effectively about:
n the purpose of testing, 
n eligibility for testing, 
n risk, 
n the accuracy of tests, 
n the meaning of test results, 
n the psychosocial effects of testing, 
n possible further interventions, and 
n impact on family members. 
Studies have shown that access to high quality, timely information:
n enhances people’s knowledge and empowerment, 
n facilitates their interaction with their health care providers and the health care
system, and 
n enables them to participate in decision-making at the level they desire51 52. 
For informed decision-making, it is essential to identify the most effective strategies
and resources to educate the public and health care providers in this rapidly
developing area.
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Both the Public and the Professions Need Education
The public has shown considerable interest in this area (Ipsos-Reid poll – September
2001) but lacks adequate knowledge about genetics and genetic testing. Similarly,
health care providers are already dealing with genetic issues in their practices. They
see a role for themselves in providing genetic services but they lack adequate
knowledge about genetics and genetic testing53. 
An informal survey of genetics courses in the undergraduate medical curricula
of Canadian medical schools, identified only five out of a total of 16 medical schools
in Canada as having explicitly designated curriculum time for genetics. However, it
is likely that genetics is integrated with other courses, rather than existing as a
specific course54.
Genetics is a rapidly expanding field and the media and commercial enterprises
will likely play a role in educating the public. Both the public and the health
professions want access to high quality educational materials. 
As interest in genetics grows, there is an urgent need to develop and evaluate
credible educational materials and strategies for health care providers and the
public. Public access to credible sources of information may minimize
misperceptions of genetics and facilitate informed choice around genetic testing. 
Our education system often emphasizes the technical perspective, sometimes to
the exclusion of related and relevant social, political, economic and moral issues,
which can lead to people choosing simple and often radical solutions to complex
problems55. Ideally, public and provider education will clarify the broader ethical,
social, and legal issues involved with genetics and reduce the stigmatization
associated with genetically determined diseases. In some cases, people may even be
able to adopt a more individualized preventive approach to their health by making
positive lifestyle choices.
Educating the Public
To make informed choices about genetic testing, the public needs a basic
understanding of genetic issues. Core genetic issues for the public include:
n a basic understanding of genetics and heredity, 
n an understanding of “risk” or probability of disease,
n the risks, benefits, limitations and meaning of genetic test results, 
n implications for the individual and family, and 
n availability and access to genetic services.
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Strategies for educating the public include: 
n media campaigns, 
n social marketing strategies, 
n credible genetic web sites, 
n public health genetic initiatives, 
n community-based educational symposia, and 
n partnerships with volunteer disease-based organizations. 
Educating Health Care Professionals
Many health care disciplines will be involved in delivering genetics services. Each
health care discipline will need to modify its genetics curriculum and competencies
to meet its specific involvement in genetics service delivery. 
Health care professionals should understand:
n the core issues of genetics, 
n the social and psychological implications of genetic information, and 
n when and how to make a genetics referral. 
Physicians will need to know about: 
n the difference between the clinical diagnosis of disease and the genetic
predisposition to disease in healthy people; 
n the impact that behavioural, social, and environmental factors have on risk and
coping;
n the importance of family history, risk assessment, and the communication of risk
information; 
n informed choice and its implications for the individual and family; 
n availability and access to genetic services;
n the range of interventions available including prevention, surveillance and
treatment options, psychosocial support and genetic counselling;
n physical and psychosocial benefits, limitations and risks of genetic testing and
information;
n the sensitivity of genetic information and the need for confidentiality; and 
n the importance of tailoring information and services to clients’ culture,
knowledge and language level.
Strategies for educating health professionals in genetics include: 
n the development, evaluation and dissemination of family history and risk
assessment tools, 
n referral guidelines, 
n communication strategies, 
n management protocols, 
n decision support tools, and 
n genetic web sites.
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As new genetic tests become available and approved, strategies will need to be
developed to educate health care professionals about disease-specific tests.
Communication strategies need to be developed, as well as innovative educational
approaches such as problem-based learning modules and train-the-trainer initiatives. 
Costs of Not Addressing Genetics Education
The consequences of not addressing education about genetics and genetic testing
could result in inappropriate genetic testing which could lead to:
n unnecessary and potentially harmful tests or treatments,
n people at increased risk not being identified,
n psychological distress in patients,
n inadequate counselling regarding risks and benefits and the meaning and
limitations of genetic testing,
n breaches of confidentiality,
n ethical dilemmas,
n family conflict, and
n overuse of health care resources and increased health care costs.
Recommendations
The Education Sub-Committee recommends:
n infrastructure support for the educational needs of the genetic testing program;
n the development, implementation and evaluation of a multi-faceted public
education strategy;
n the Ministry of Education review and revise curricula for educating students in
elementary and secondary schools to ensure that applied, relevant, and
appropriate genetics and related topics are incorporated into courses; 
n a strategy to educate current health care professionals about core genetic issues
with special emphasis on knowledge translation and management;
n the Ministry of Colleges and Universities review and revise genetics components
of curricula of post-secondary schools, especially for health profession training
programs, but also in all science programs 55;
n the development of a framework for implementation of education for new
disease-specific genetic tests;
n partnering with volunteer organizations, Deans of health professional schools in
Ontario and other appropriate educational organizations to develop educational
materials, curricula and strategies for the public and health professions;
n evaluating educational materials and strategies and continually improving
genetics educational programs;
n tailoring genetics educational programs, information and services to culture,
knowledge and language level.
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Section 3: Recommendations of the
Provincial Advisory Committee on
New Predictive Genetic Technologies
An Ongoing Provincial Genetics Advisory Committee 
1. Recommendations made by the Advisory Committee are broadly based and far-
reaching. The Committee therefore recommends that the need for further
consultation and implementation be recognized through an ongoing process.
With this in mind, it is recommended that Ontario establish a Provincial
Genetics Advisory Committee to advise on genetic services in the Province of
Ontario. The committee should provide advice to the Government of Ontario
through the Deputy Minister of Health and Long-Term Care in the following
areas: 
n New developments in the genetic sciences,
n Evaluation of existing genetic services, and
n Recommendations on the timely provision of new genetic tests and services
following formal evaluation of proposed genetic testing by the committee. 
n Legal and ethical issues, 
n Human and infrastructure resource requirements for genetic services, 
n Educational needs for Ontarians, including professions involved in all aspects
of the provision of genetic services, 
n A process for the implementation of new genetic services that includes both
public and private laboratories,
n Any other areas as requested by the provincial government.
The committee’s membership should be reflective of the broad based expertise
necessary to achieve its mandate including geneticists, genetic counsellors,
health economists, legal/ethical experts, epidemiologists, laboratory scientists,
mental health professionals, and community representatives, including members
of health related voluntary organizations. Liaison positions should exist with
other relevant committees, such as the Test Review Committee under the
Quality Management Programs/Laboratory Services (QMPLS) of the Ministry of
Health and Long-Term Care (MOHLTC).
Approach to Introduction of New Genetic Tests and Services
2. Ontario should ensure that new genetic services are evaluated on the basis of
technical accuracy (‘analytical validity’), clinical effectiveness (clinical validity),
usefulness to tested individuals (clinical utility), adverse and additional effects,
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expansion potential and cost (social utility), ethical/legal implications and
resource implications. This evaluation will require the participation of experts
and should include the perspective of relevant stakeholders including patients,
their families and the community. 
3. The evaluation framework developed by the Advisory Committee should be the
basis of the evaluation process for new services. This evaluation process should
include all aspects of genetic services including legal, ethical, social,
psychosocial, epidemiological, clinical and laboratory components.
4. Implementation of new tests should only be considered after a review of the
expected downstream impacts, including psychological impacts on patients, and
the balance between the costs of the introduction of the new genetic test against
other strategies for the prevention of illness.
5. Whenever new tests are introduced which affect an identifiable community, that
community should be involved from the earliest stages of planning. The
promotion, uptake and diffusion of new genetic services should acknowledge
the cultural diversities and needs of the people of Ontario.
6. Ontarians should be provided with equitable timely access to genetic services
across Ontario. Furthermore, any Ontarian should have access to genetic
services if they have concerns about their genetic risks.
7. Where new genetic services are introduced, clear guidelines and care maps
where appropriate, should be developed and made available as to what is
expected in the genetic management of the condition. 
8. Where predictive testing will not alter the onset of disease [e.g. Huntington
Disease], genetic testing should still be considered because other potential
benefits may exist.
Programmatic Genetic Services
9. Genetic testing should be provided as part of an integrated, multidisciplinary
service, incorporating genetic assessment and counselling, quality testing,
psychosocial support and follow-up services, including surveillance, prevention
and treatment, as appropriate. 
10. Psychosocial and emotional support services, being fundamental to the
genetic consultation process, should be integrated into genetics service
provision and access to psychosocial support services should be available
throughout the province. 
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Education And Information
11. Ontario should undertake to develop and promote a genetics educational
program for Ontarians, to meet public and professional needs through
n a multifaceted public education program;
n fostering appropriate education of health professionals at undergraduate,
graduate, post graduate and continuing educational levels.
12. Providers and the public should receive timely information concerning the
availability of new predictive genetic services, criteria recommended for
application, and resources available to patients accessing services. This
framework should include a variety of methods for disseminating genetic
information to provide:
n an index of genetic services available in Ontario; 
n information for each new genetic test to health providers, including provincial
guidelines for referral to genetic services, eligibility for genetic testing, access
to testing and counselling, risk assessment, prevention and surveillance
strategies, an outline of financial, ethical, legal and psychosocial implications
of the test, and information on further information sources for patients.
Quality Management And Guidelines
13. Each aspect of genetic services in Ontario requires quality management and
guidelines that applies to:
n The pretest preparation (counselling, education materials, etc.);
n Analytical (laboratory tests and their interpretation);
n Post-analytical follow-up (interpretation and reporting to patients;
n Patient monitoring following testing.
14. Where an approved genetic test is not provided in the province, Ontario should
ensure that samples for testing are sent only to accredited laboratories in other
jurisdictions, with acceptable quality assurances programs. 
Human Resources For Genetic Services
15. The human resources and health system impact that will result from increasing
demand for genetic services must be addressed if the province is to respond to
this pressure. This is especially important, given the probable rapid uptake of
these new technologies and the long lead time required to train professional
personnel. This should include strategies to:
n encourage retention and recruitment of personnel involved in the delivery of
genetic services to genetics training programs; 
n introduce or enhance accredited training programs for genetic services; 
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n ensure that all personnel directly involved in genetic services work in a
regulated health environment. The issue of regulation of professions involved
in the delivery of genetic services who are currently not regulated should be
examined following further consultation.
Non-Discrimination
16. The Legislature should consider amending the Human Rights Code to prevent
discrimination on the basis of genetic traits. This could be done by explicitly
including “genetic trait” as a prohibited ground of discrimination in Part 1, or,
as the Ontario Law Reform Commission recommended in its 1996 Report, by
amending the definition of “because of handicap” in section 10(1). If the
Legislature adopts the latter course of action, the Human Rights Commission
should issue an interpretive rule providing that genetic conditions, both present
and future, fall within the ambit of its legislative protection.
17. The government should consider establishing measures that are proactive in
avoiding discriminatory uses of genetic information. To this end, the committee
recommends that the government establish an approval system for the use of
genetic testing and genetic information in the contexts of insurance,
employment and any other domains outside of health care where the use of
genetic testing and genetic information could have negative or undesirable social
consequences. 
18. The government should consider implementing a moratorium that would
prevent insurance companies and employers from using genetic information to
determine eligibility for insurance or employment. This moratorium should
remain in effect until proper policies and processes with respect to the use of
genetic information in these contexts are implemented.
Research Review
19. The government should ensure that all genetic testing undertaken in the
research context in Ontario will have thorough research ethics review by
independent and accountable research ethics boards. 
Patents, Direct Marketing and Commercialization of Genetic Tests
20. The committee recommends that the government of Ontario engage in
discussions with the government of Canada regarding patents, direct to
consumer marketing and other areas of federal jurisdiction related to the
commercial use of genetic tests. 
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Informed Consent
21. The Committee recommends that informed consent with regard to predictive
genetic testing should be express and documented, notwithstanding section
11(4) of the Health Care Consent Act, 1996 which provides that consent may be
expressed or implied. Express consent represents the culmination of an
informed consent process in which an individual is provided information about
the potential risks and benefits of, and alternatives to, the proposed genetic test.
It confirms the voluntary nature of genetic testing and the right of the individual
to withdraw his or her consent. 
Genetic Testing of Minors
22. Newborns and children should not be tested for genetic conditions where there
are no timely medical or psychosocial benefits, or where these benefits will not
accrue until adulthood (as in the case of carrier status or adult-onset disease). 
23. As a general rule, parental consent should be required for newborn genetic
screening. The Provincial Advisory Committee, or another body accountable to
the government, should investigate whether, and under what circumstances,
newborn screening without express parental consent is permissible. 
24. The practice of banking newborn screening data and samples should be
reviewed with a view to ensuring that individual rights of privacy and
confidentiality are protected and that informed consent is integral to this
practice. This review should include the issue of the reuse or testing of banked
newborn samples. 
Privacy and Confidentiality of Genetic Information
25. Within the context of privacy legislation, the government should enact
legislation to protect the privacy of genetic information. This legislation should
particularly address the following issues:
n the privacy and control of information obtained from laboratory testing, as
well as blood and tissue samples;
n the establishment of norms for the collection and storage of genetic
information;
n the establishment of norms for determining who should have access to stored
genetic information and genetic samples, including physicians and other
health professionals;
n a tested individual’s right to request that his or her DNA sample be destroyed;
n the banking of newborn screening data and samples;
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n standards of confidentiality regarding an individual’s genetic information as
relates to other family members; 
n the creation and treatment of genetic records as distinct from medical records.
26. (a) Legislation should not impose a duty to disclose genetic information to high
risk relatives. 
(b) The issue of physician privilege to disclose genetic information to an
individual’s high-risk relatives against his or her wishes, should be reviewed. 
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Section 4: Appendices
Appendix A
Provincial Advisory Committee on New Genetic 
Predictive Technologies
Terms of Reference
Purpose
The Ministry of Health and Long-Term Care (MOHLTC) wishes to develop
strategies and policies proactively in the area of predictive genetic testing in order
for Ontario to keep pace with this rapidly evolving area of services for the
improvement of health and the alleviation of human suffering.
The purpose of the committee is to develop principles/guidelines/broad criteria
to guide operational decision making by MOHLTC in introducing new genetic
predictive technologies in Ontario. The breadth of expertise required for the
committee must include expertise across the broad array of clinical, technical,
financial, psychosocial, ethical and legal concerns. 
Pac Terms of Reference
To provide advice to MOHLTC regarding the future of predictive genetic testing,
with specific reference to:
1. the extent to which predictive genetic testing will present an opportunity, and to
which testing services will impact on the health care system and people of
Ontario over the short term (two to three years) and the longer term (ten years);
2. a framework MOHLTC can use to reach future funding decisions relating to new
predictive genetic tests and treatment modalities that might become available
over the next five years;
3. criteria for choosing the sites for predictive genetic testing services, taking into
account the existing programs which would complement and facilitate delivery
of service, access for patients and persons at risk, availability of genetic
counselling and patient care, and the volume of activity to support appropriate
turn around times and skill development. Of special interest is the extent to
which a centralized or decentralized program will provide maximum efficiencies
for common and less-common testing and the economy of scale that might be
achieved through high volumes;
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4. a framework for continuous evaluation of changing technology and research and
how these will be incorporated into ongoing services;
5. a framework to be used to evaluate new genetic screening modalities once
introduced
6. a framework for ensuring broad quality assurance issues are met;
7. broad issues regarding the collection and sharing of information;
8. ethical, legal and social implications including informed consent, privacy and
confidentiality, and familial implications; 
9. issues concerning genetic discrimination and stigmatization which could be
faced by people or groups seeking employment, life insurance, adoption,
immigration, or in any other endeavour;
10. how best to deal with education of providers, patients and the general
population; 
11. how best to deal with psychological factors which may occur in the tested
population;
12. a framework for distinguishing between appropriate and inappropriate genetic
testing;
13. a framework for distinguishing between what genetic screening testing should
be publicly funded and what excluded.
n The Committee will be informed regarding any Federal-Provincial initiatives
in these areas and will give consideration to incorporate the products of these
initiatives as appropriate. It is also envisaged that the products of the
provincial committee will inform the work of the Federal-Provincial initiative. 
n The Committee will ensure that all recommendations for a framework are
informed, to the extent possible, of approaches being taken in other
jurisdictions, particularly those with a publicly funded health care system. 
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Sub-Committees
A sub-committee structure will be used to assemble the proposed framework for the
introduction of new genetic predictive technologies. 
Although there will be overlap, the sub-committees should consider the
following areas in the development of their guidelines:
n criteria to assess the validity and utility of a new technology,
n guidelines for implementation,
n guidelines for ongoing monitoring and evaluation, 
n human and capital resource requirements relating to the short term and the
five year view,
n translation of research into service relating to the short term and the five year
view,
n approaches taken by other jurisdictions, as appropriate,
n commercialization and the role of the private sector, 
n data management.
1. Clinical Sub-Committee
To examine all issues of a clinical nature in regard to new predictive genetic
technologies, including:
n Development of eligibility criteria for testing (taking into account validity and
utility);
n Development of guidelines for offering testing to persons at risk;
n Development of guidelines for facilitating 
n mechanisms for referrals 
n access to testing 
n access to all related services
n management of persons changing from at-risk to affected status
n Development of guidelines for service standards and requirements; 
n Development of recommendations regarding pre- and post-test counselling,
and patient follow up; 
n Regulatory requirements.
2. Psychosocial Sub-Committee 
n Develop strategies for addressing the psychosocial implications of genetic
screening as these relate to persons at risk and their family members and where
necessary, for intervention;
n Develop recommendations for screening persons at risk requiring psychosocial
counselling, including management of persons changing from at-risk to
affected status.
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3. Laboratory Sub-Committee
To examine all issues regarding laboratory predictive genetic testing, including:
n appropriate technology;
n quality assurance;
n laboratory licensing;
n laboratory insurance;
n specimen repository and data management;
n development of laboratory expertise;
n necessary volumes per test;
n monitoring and making recommendations regarding new technological
developments;
n criteria for selecting testing sites;
n appropriate turn around times;
n standardized reporting;
n transportation requirements for samples;
n regulatory requirements;
n patent issues; 
n partnership issues, including commercialization and role of the private sector;
n communication and privacy issues.
4. Legal and Ethical Sub-Committee
Development of mechanisms to address the legal and ethical implications of genetic
predictive testing, including:
n consent; 
n privacy; 
n confidentiality of patient and family health information;
n discrimination;
n coercion;
n access;
n role of the private sector;
n patent issues;
n patient recall;
n multiple tests on the same sample for the same condition and for multiple
conditions;
n management of persons changing from at-risk to affected status.
5. Resource Assessment and Utilization Sub-Committee
Incorporation of the issues below into the decision-making framework:
n human resources and capital planning;
n integration into current health services;
n mechanisms for ensuring appropriate utilization of new predictive technologies.
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6. Education Sub-Committee
n Develop recommendations for modalities and approaches to public, patient and
provider education requirements, including adult education, literacy, translation;
n Review educational modalities currently available provincially, nationally and
internationally.
7. Evaluation Sub-Committee
n Develop an evidence-based framework for evaluation of validity of new genetic
predictive technologies;
n Develop criteria for ongoing evaluation of each new genetic predictive test
implemented;
n Develop proposal for evaluation of benefits, risks, costs, and affordability for
each new genetic test being considered for implementation;
n Develop proposal for evaluation of the framework under development by the
Advisory Committee on New Genetic Predictive Technologies.
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Appendix B
Provincial Advisory Committee on New Predictive 
Genetic Technologies
Membership
Dr. Judith Allanson, Genetics Program, Children’s Hospital of Eastern Ontario
Sharon Balsys, Senior Advisor, Communications and Information Branch, Ministry
of Health and Long-Term Care
Dr. Sean Blaine (Co-Chair, Education Sub-Committee), Assistant Professor,
Department of Family and Community Medicine, University of Toronto, Research
Scholar Family Health Care Research Unit
Dr. George Browman (Chair, Evaluation Sub-Committee), CEO, Hamilton Regional
Cancer Centre
Dr. June Carroll, Co-Chair, Education Sub-Committee, Associate Professor, Sydney
G Frankfort Chair in Family Medicine, Department of Family and Community
Medicine, University of Toronto, Family Medicine Centre, Mount Sinai Hospital,
Representative of the Ontario College of Family Physicians
Dr. David Cole, Depts. of Laboratory Medicine & Pathobiology, Medicine, and
Pediatrics (Genetics), University of Toronto, Director, Adult Genetics Services,
University Health Network
Dr. Colin D’Cunha, Director and Chief Medical Officer of Health, Public Health
Branch, Ministry of Health and Long-Term Care
Dr. Mary Jane Esplen (Chair, Psychosocial Sub-Committee), Head, Program of
Psychosocial & Psychotherapy Research in Cancer Clinician Scientist, Dept of
Psychiatry, Mount Sinai Hospital
Dr. Alasdair Hunter (Co-Chair, Clinical Sub-Committee), Director, Genetics
Program, Children’s Hospital of Eastern Ontario 
Phil Jackson, Director, Strategic Health Policies Branch, Ministry of Health and
Long-Term Care
Dr. Birthe Jorgensen, Projects Manager, Medical Advisory Secretariat, Ministry of
Health and Long-Term Care
Michael Kilpatrick, Senior Policy Analyst, Medical Advisory Secretariat, Ministry of
Health and Long-Term Care
Trudo Lemmens, (Co-Chair, Legal and Ethical Issues, Sub-Committee), Assistant
Professor, Faculty of Law, University of Toronto 
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Dr. Les Levin, Senior Medical Advisor, Head, Medical Advisory Secretariat, Ministry
of Health and Long-Term Care
Dr. Alex MacKenzie, Director of Research Institute, Children’s Hospital of Eastern
Ontario
Grace Maddox, Vice-President (volunteer), Ontario Division, Canadian Cancer
Society
Dr. Roxanne Mykitiuk, (Co-Chair, Legal and Ethical Issues Sub-Committee)
Associate Professor, Osgoode Hall Law School, York University
Leela Prasaud, Manager, Quality Management, Laboratories Branch, Ministry of
Health and Long-Term Care
Dr. Kenneth P.H. Pritzker, Pathologist-in-Chief, Mount Sinai Hospital
Maureen Provencher, Program Consultant Operations, Hospital & Priority Programs
Unit, Ministry of Health and Long-Term Care
Francine Robert, Genetics Nurse, North Bay and District Health Unit 
Dr. Kirsten Rottensten, Public Health Branch, Ministry of Health and Long-Term Care
Dr. Brian Sheridan, Vice President, Medical Affairs, Canada, MDS Laboratory
Services, Representative of the Ontario Association of Medical Laboratories 
Dr. Anne Summers (Chair, Advisory Committee on New Predictive Genetic
Technologies), Genetics Program, North York General Hospital
Elaine M.W.Taylor, Chair, Huntington Society of Canada
Adam Topp, VP & Chief Financial Officer, Sunnybrook and Women’s Health
Sciences Centre
Luke A. Vanneste, Senior Vice President, Bank of Nova Scotia
Dr. Lea Velsher (Co-Chair, Clinical Sub-Committee), Clinical Genetics, North York
General Hospital
Charlotte Weiss, Legal Counsel, Ministry of Health and Long-Term Care
Dr. Philip Wyatt (Chair, Laboratory Sub-Committee), Genetics Program, North York
General Hospital 
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Sub-Committee Chairs and Members
Education Sub-Committee
Dr. Sean Blaine, Co-Chair, Assistant Professor, Department of Family and
Community Medicine, University of Toronto, Research Scholar at Family Health
Care Research Unit
Dr. June Carroll, Co-Chair, Associate Professor, Sydney G Frankfort Chair in
Family Medicine, Department of Family and Community Medicine, University of
Toronto, Family Medicine Centre, Mount Sinai Hospital, Representative of the
Ontario College of Family Physicians
Sharon Balsys, Senior Advisor, Communications and Information Branch, Ministry
of Health and Long-Term Care
Morag Bell, Genetic Counsellor, Credit Valley Hospital
Dr. Annette Burfoot, Associate Professor, Department of Sociology, Queen’s
University
Dr. Niall Byrne, Centre for Research in Education, Faculty of Medicine, University
of Toronto
Dr. Mary Jane Esplen, Head, Program of Psychosocial & Psychotherapy Research in
Cancer Clinician Scientist, Dept of Psychiatry, Mount Sinai Hospital
Dr. Ian Johnson, Assistant Professor, Dept of Public Health Sciences, University of
Toronto
Margaux Lachance, Genetic Nurse Consultant, Northeastern Regional Cancer Care
Centre
Dr. Wendy Meschino, Genetics Program, North York General Hospital
Grace Maddox, Vice-President (volunteer), Ontario Division, Canadian Cancer
Society
Jennifer Poudrier, Research Assistant, Dept. of Sociology, Queen’s University
Evaluation Sub-Committee
Dr. George Browman, Chair, CEO, Hamilton Regional Cancer Centre
Dr. Bharati Bhapat, Geneticist, Pathology and Laboratory Medicine, Mount Sinai
Hospital 
Dr. Andrea Eisen, Assistant Professor, McMaster University, Medical Oncologist,
Hamilton Regional Cancer Centre
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Dr. Michael Evans, CCFP, Principal Investigator, Knowledge Translation Program,
Research Scholar, Family Healthcare Research Unit, Staff Physician, Toronto Western
Hospital, University Health Network; Asst. Professor, Dep’t of Family & Community
Medicine, University Of Toronto
Dr. Sandra Farrell, Medical Director, Regional Genetics Program, The Credit Valley
Hospital
Dr. Mita Giacomini, Associate Professor, Centre for Health Economics & Policy
Analysis, Dept. of Clinical Epidemiology and Biostatistics, McMaster University
Dr. Fiona Miller, Associate Professor, Department of Clinical Epidemiology and
Biostatistics, Member, Centre for Health Economics and Policy Analysis, McMaster
University
Dr. Kirsten Rottensten, Public Health Branch, Ministry of Health and Long-Term Care
Elaine M. W. Taylor, Chair, Huntington Society of Canada
Psychosocial Sub-Committee
Dr. Mary Jane Esplen, Chair, Head, Psychosocial and Psychotherapy Research in
Cancer Genetics, Assistant Professor & NCIC Scientist, Department of Psychiatry,
Faculty of Medicine, University of Toronto, Mount Sinai Hospital/ Samuel Lunenfeld
Research Institute
Melyssa Aronson, Genetic Counsellor, Familial Gastrointestinal Cancer Registry,
Mount Sinai Hospital
Dr. Mario Cappelli, Clinical Psychologist, Mental Health Program, Children’s
Hospital of Eastern Ontario, Clinical & Assistant Professor of Psychology, Pediatrics,
Graduate & Postdoctoral Studies, University of Ottawa, Allied Health Clinical
Scientist, Children’s Hospital of Eastern Ontario Research Institute
Cathy Gilles, Genetic Counsellor, Genetic Counselling Program, Thunder Bay
District Health Unit
Margaux Lachance, Genetic Nurse Consultant, Northeastern Regional Cancer Care
Centre
Alexander Liede, Genetic Counsellor, Centre for Research in Women’s Health,
University of Toronto
Dr. Jon Hunter, Head, Psychosomatics Program, Dept. of Psychiatry, University of
Toronto, Mount Sinai Hospital
Francine Robert, Genetics Nurse, North Bay and District Health Unit 
Dr. Allen Swayze, Psychiatrist, Toronto
Nancy Webb, Director, Toronto Huntington Disease Resource Centre
84 Genetic Services in Ontario: Mapping the Future
Clinical Sub-Committee
Dr. Alasdair Hunter, Co-Chair, (retired), Director, Genetics Program, Children’s
Hospital of Eastern Ontario
Dr. Lea Velsher, Co-Chair, Clinical Genetics, North York General Hospital
Richard Birthwhistle, Professor, Departments of Family Medicine and Community
Health and Epidemiology, Queen’s University
Dr. William Feldman, Professor Emeritus of Pediatrics, University of Toronto,
Editor-in-chief, Annals, Royal College of Physicians and Surgeons of Canada.
Andrea Shugar, Genetic Counsellor, Canadian and American Board-Certified Genetic
Counsellor 
Dr. Gary Viner, Assistant Professor, Department of Family Medicine, University of
Ottawa
Dr. Philip Wells, Canada Research Chair in Thromboembolic Diseases, Chief,
Division of Hematology, Ottawa Hospital
Legal & Ethical Issues Sub-Committee
Trudo Lemmens, Co-Chair, Assistant Professor, Faculty of Law, University of
Toronto 
Roxanne Mykitiuk, Co-Chair, Associate Professor, Osgoode Hall Law School, York
University
Bita Amani, Graduate Fellow, Centre for Innovation Law and Policy, University of
Toronto
Lisa Austin, Assistant Professor, Faculty of Law, University of Toronto
Mireille Lacroix, Research Associate, Faculty of Law, University of Toronto
Charlotte Weiss, Legal Counsel, Ministry of Health and Long-Term Care
Resource Assessment and Utilization Sub-Committee
Adam Topp, Chair, Vice President & Chief Financial Officer, Sunnybrook and
Women’s Health Sciences Centre
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Laboratory Sub-Committee
Dr. Philip Wyatt, Chair, Genetics Program, North York General Hospital 
Dr. Sylvia Asa, Pathologist-in-Chief, University Health Network & Toronto Medical
Laboratories
Dr. Nancy Carson, Head, Molecular Genetics Diagnostic Laboratory, Children’s
Hospital of Eastern Ontario
Vince D’Mello, Deputy Registrar, The College of Medical Laboratory Technologists
of Ontario
Dr. Joel Goodman, Vice President, Clinical Operations Gamma-Dynacare Medical
Laboratories, Representative of the Ontario Association of Medical Laboratories 
Joanne Miyazaki, Manager Business Development, Quality Management Program –
Laboratory Services
Leela Prasaud, Manager, Quality Management, Laboratories Branch, Ministry of
Health and Long-Term Care
Dr. Kenneth Pritzker, Pathologist-in-Chief, Department of Pathology and Laboratory
Medicine, Mount Sinai Hospital
Dr. Brian Sheridan, VP, Medical Affairs, Canada, MDS Laboratory Service
Representative of the Ontario Association of Medical Laboratories 
Dr. Sherryl Taylor, Co-Director, DNA Diagnostic Laboratory, Kingston General
Hospital, Professor, Queen’s University
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Appendix C
Molecular Genetic Tests Offered In Ontario 
(Source: GeneTests-Gene Clinics: Human Genetics Information Resource, 2001)
Clinical tests are available for:
22q11 Deletion Syndrome 
Achondroplasia 
Alpha-1-Antitrypsin Deficiency 
Alpha-Thalassemia 
Angelman Syndrome 
Apert Syndrome 
Beckwith-Wiedemann Syndrome 
Beta-Thalassemia 
BRCA1 Hereditary Breast/Ovarian Cancer 
BRCA2 Hereditary Breast/Ovarian Cancer 
CADASIL 
Canavan Disease 
Charcot-Marie-Tooth Neuropathy Type 1A 
Charcot-Marie-Tooth Neuropathy Type X 
Congenital Bilateral Absence of the Vas Deferens 
Crouzon Syndrome 
Cystic Fibrosis 
Cystinosis 
DFNA 3 (Connexin 26) 
DFNB 1 (Connexin 26) 
DRPLA 
Duchenne/Becker Muscular Dystrophy 
Fabry Disease 
Facioscapulohumeral Muscular Dystrophy 
Factor V Leiden Thrombophilia 
Fragile X Syndrome 
FRAXE Syndrome 
Friedreich Ataxia 
Gaucher Disease 
Genotypic Gender Assignment 
Hemoglobin C 
Hemoglobin E 
Hemoglobin S 
Hereditary Hemochromatosis 
Hereditary Neuropathy with Liability to Pressure Palsies 
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Hereditary Sensory Neuropathy Type I 
Hexosaminidase A Deficiency 
Huntington Disease 
Hyperkalemic Periodic Paralysis 
Hypochondroplasia 
Ichthyosis, X-Linked 
Jackson-Weiss Syndrome 
Kallmann Syndrome, X-Linked 
Leber Hereditary Optic Neuropathy 
Marfan Syndrome 
Medium Chain Acyl-Coenzyme A
Dehydrogenase Deficiency 
Mental Retardation Syndromes, Undiagnosed 
Miller-Dieker Syndrome 
MTHFR Thermolabile Variant 
Mucopolysaccharidosis Type II 
Muenke Syndrome 
Multiple Endocrine Neoplasia Type 1 
Multiple Endocrine Neoplasia Type 2
Myotonic Dystrophy Neurofibromatosis 1 
Oculopharyngeal Muscular Dystrophy 
Parentage Testing 
Pfeiffer Syndrome Type 1, 2, and 3 
Polycystic Kidney Disease 1, Autosomal
Dominant 
Polycystic Kidney Disease 2, Autosomal
Dominant 
Prader-Willi Syndrome 
Prothrombin G20210A Thrombophilia 
Retinoblastoma 
Rh D Genotyping 
RNA Banking 
Saethre-Chotzen Syndrome 
Schimke Immunoosseous Dysplasia 
Sex-Determining Region Y 
Simpson-Golabi-Behmel Syndrome 
Smith-Magenis Syndrome 
Spinal and Bulbar Muscular Atrophy 
Spinal Muscular Atrophy 
Spinocerebellar Ataxia Type 1 
Spinocerebellar Ataxia Type 2 
Spinocerebellar Ataxia Type 3 
Spinocerebellar Ataxia Type 6 
Spinocerebellar Ataxia Type 7 
Spinocerebellar Ataxia Type 8 
Research tests are available for:
Autism 
Cleft Lip/Palate Syndrome 
Dysplastic Nevus Syndrome 
Ectodermal Dysplasia
Ectrodactyly 
Episodic Ataxia Type 2 
Familial Adenomatous Polyposis 
Familial Hemiplegic Migraine 
Familial Malignant Melanoma 
Familial Vestibulopathy 
FAMMM, Familial Atypical Multiple 
Mole Melanoma Syndrome
Ontario Ministry of Health and Long-Term Care 
Approved Laboratories That Provide Predictive Genetic Testing 
1. Children’s Hospital of Eastern Ontario, DNA Diagnostic Laboratory, Ottawa
2. Hospital for Sick Children Molecular Genetics Laboratory, Toronto
3. London Health Sciences Centre, Molecular Diagnostic Laboratory, London
4. Kingston General Hospital, DNA Diagnostic Laboratory, Kingston
5. McMaster University Medical Centre, Ontario Provincial Hemoglobinopathy,
Hamilton
6. Mount Sinai Hospital, Toronto 
7. North York General Hospital, Molecular Genetics Laboratory, Toronto 
8. The Credit Valley Hospital, Genetics Laboratory, Ontario 
In addition to these laboratories, numerous research laboratories throughout the
province of Ontario provide genetic testing on a research basis. 
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Telomere Detection 
Thanatophoric Dysplasia Type I 
Thanatophoric Dysplasia Type II 
Uniparental Disomy Testing, General 
Williams Syndrome 
X Inactivation Studies 
Y Chromosome Deletion 
Y Chromosome Detection/Molecular
Genetics 
Zygosity Testing 
Febrile Convulsions 
Hereditary Non-Polyposis Colon Cancer 
Hirschsprung Disease, HSCR
MTHFR Deficiency 
Osteoporosis 
Progressive Myoclonus Epilepsy, Lafora Type 
Russell-Silver Syndrome 
Severe Speech Delay 
Wiskott-Aldrich Syndrome 
Appendix D
Glossary of Terms for Genetic Disorders and Genetic Testing
Autosomal dominant disorders
Disorders where inheritance of a mutation from one parent only (or arising anew
during egg or sperm formation) can be sufficient for the person to be affected.
Dominant disorders include familial hypercholesterolaemia, Huntington Disease,
adult polycystic kidney disease and neurofibromatosis.
Autosomal recessive disorders
Disorders, where for a person to be affected, a mutation has to be inherited from
both biological parents. Such parents are usually unaffected carriers because they
only have a single copy of the affected gene. Common recessive disorders include
cystic fibrosis, sickle cell disease and thalassemia.
Carrier
For a recessive disorder, where two copies of the mutation must be present for the
clinical condition to be manifested, the individual who carries only one copy of the
mutation (heterozygote) is described as being a carrier. Usually, these individuals
are unaffected by the clinical condition, but in some cases, subtle differences might
be detectable. For example, a carrier of sickle cell disease is well, but a small
percentage of their red blood cells have a sickle shape under selected laboratory
conditions. 
Compound Heterozygote – (see also heterozygote)
Both copies of the gene are mutated, but they are different mutations. For example,
there might be a base-pair alteration at one location (e.g. codon 10) in one copy and
a deletion at another location (e.g. codon 12) in the other copy of the gene. Most
persons with recessive disorders are compound heterozygotes. 
Diagnostic genetic test
Diagnostic testing is performed on individuals with clinical signs of a potential
disease or condition. The purpose of the testing is to make a diagnosis of whether or
not the person currently has a specific disorder. For example, a person with muscle
weakness and cramps will be diagnosed as having a clinical sign called myotonia.
DNA testing could then be initiated to determine what type of myotonia they have.
This gives a specific diagnosis or alternatively, can rule out other specific diagnoses. 
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Expressivity (or variable expressivity)
Expressivity is the degree to which an affected person manifests the disorder. There
might be such subtle expression that the person is unaware they have the disorder.
There can be significant variation within and between families. For example, for the
BRCA1 and 2 genes, a woman might have bilateral breast cancer, but no ovarian
cancer, while her sister might develop only ovarian cancer. In this case, the disorder
is expressing itself variably in different women, even in the same family.
Gene
The fundamental hereditary unit; a sequence of chromosomal DNA that is required
for the production of a functional product, usually a protein.
Genetic disorders or diseases
Conditions that are due to alterations in the genetic endowment of an individual.
They may be the direct consequence of defects in single genes; or in whole
chromosomes, parts of which may be lost, duplicated or misplaced; or due to the
interaction of multiple genes and external factors.
Genetic Screening 
Genetic screening may be defined as any kind of test performed for the systematic
early detection or exclusion of a genetic disease, the predisposition or resistance to
such a disease, or to determine whether a person carries a gene variant that may
produce disease in offspring. Screening may be concerned with the general
population or with specific sub-populations defined on some basis other than their
health.
Distinctions should be made between reproductive screening (prenatal screening
to find affected pregnancies, and carrier screening to find persons who may pass on
disease to offspring), or screening individuals for genetic risks to their own health
(screening for predisposition to disease, for presymptomatic disease, for those
affected with disease)
Screening can be population-based (i.e. newborns, pregnant women, individuals
of a certain age) or selective, where a specified subset of a population is targeted (i.e.
individuals from populations known to be at increased risk; for example, those of
Mediterranean heritage are at increased risk of thalassemia)
Genetic test
All laboratory procedures on a specimen(s) to detect the presence or absence of, or
change in, a particular gene or chromosome, or a change in a gene product, in
relation to a genetic disorder when the results describe heritable information that
can be linked directly to an individual or circumscribed population.
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Genome:
All the genetic material containing the entire genetic information in the
chromosomes of a particular organism (in humans, about three thousand million
base pairs per single chromosome set)
Genomics
The field of genetics concerned with studies of the genome.
Heterogeneity 
Heterogeneous diseases have the same clinical expression, but multiple genetic
causes. For example, at least two different mutations can produce the clinical
condition of adult-onset polycystic kidney disease. Thus, polycystic kidney disease
is genetically heterogenous. 
Heterozygote (Heterozygous) 
There are two copies of most genes (some are present in even more copies). If one is
mutated, the person is heterozygous for that mutation, meaning they have one
normal copy and one altered (mutated) copy (see also carrier). 
Homozygote (Homozygous) 
There are two copies of most genes (some are present in even more copies). If both
copies of the gene are similar, either normal or mutated, the person is homozygous
(either homozygous normal or homozygous for the mutation).
Multifactorial disorders
Disorders whose genetic components work with other, often environmental, factors
in determining a disease outcome.
Mutation
The change in a gene or chromosomes that causes a disorder or the inherited
susceptibility to a disorder.
Orphan Disease 
An orphan disease is rare. SACGT defines a rare disease or condition as having a
prevalence of less than one in 2,000 individuals, or an incidence of less than one in
10,000 individuals.
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Penetrance 
For some disorders, only a percentage of persons with the mutation will manifest
the disorder. The penetrance is the proportion of individuals with the mutation who
manifest the disorder. In a disorder with 80% penetrance, 80% of persons with the
mutation will have some manifestation of the disorder, while 20% will show no
signs of the disorder, even on careful clinical examination. The disorder could be
described as being not fully penetrant, since not every person with the mutation gets
the disorder.
Predictive genetic test
Predictive testing is performed on individuals with no clinical signs of the potential
disease or condition for which they are being tested. The test is done to determine if
the person has the mutation for the disorder, and therefore, indicate if the person is
likely to develop the disorder in the future.
Depending on the disorder, some predictive tests provide information about an
increased risk, but do not provide a definitive prognosis. For example, BRCA1/2
mutations for hereditary breast and/or ovarian cancer: the presence of the mutation
indicates increased risk, but the individual with a mutation might never develop
breast or ovarian cancer, even at an elderly age.
Other kinds of predictive tests will give virtually certain knowledge of the future
onset of a disorder (sometimes called presymptomatic tests). For example, if a test
for the mutation leading to Huntington disease shows that the person has the
mutation, the person will manifest the disease, assuming they live long enough. 
Protein
A molecule composed of one or more chains of amino acids in a specific order: the
order is determined by the sequence of bases in the gene coding for the protein.
Proteins are involved in all aspects of the body’s structure and function. 
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Appendix E
Sub-Committee Reports and Other Documents 
Produced for the Committee
Draft Report of the Legal and Ethical Issues Sub-Committee, Ontario Provincial
Advisory Committee on New Predictive Genetic Technologies, November 29, 2001
Committee members: Lemmens T, Mykitiuk R, Lacroix M, Austin L, Amani B 
Final Report of the Evaluation Sub-Committee, Evaluation Framework for
Assessing Predictive Genetic Tests, Ontario Provincial Advisory Committee on
New Predictive Genetic Technologies, November 1, 2001
Committee members: Bhapat B, Browman GP, Eisen A, Evans M, Farrell S,
Giacomini M, Miller F, Rottensten K, Taylor E
Background Papers – Evaluation Subcommittee:
n Giacomini M, Miller F, Browman G, Confronting ‘Grey Zones’ in Human
Technology Assessment: A Three-Dimensional Model for Evaluating Genetic
Testing Services for Public Insurance Coverage in Canada, November 1, 2001
n Browman G, Eisen A, Farrell S, Assessing Analytic and Clinical Validity of
Genetic Predictive Technologies and Systematic Review Methods
n Eisen A, Farrell S, Process of Template Development
n Giacomini M, Miller F, O’Brien B, But What Will They Really Cost? Economic
Considerations for the Public Funding of Emerging Genetic Tests 
n Miller F, Giacomini M, Evaluating Predictive Genetic Technologies: The Ontario
Case in Perspective
n Miller F, Giacomini M, Defining the Characteristics of Predictive Genetic Tests: A
Framework for Evaluation Decision-Making 
Final Report of the Laboratory Sub-Committee, Ontario Provincial Advisory
Committee on New Predictive Genetic Technologies, November 2001 
Committee members: Asa S, Carson N, D’Mello V, Goodman J, Miyazaki J, Prasaud
L, Pritzker K, Sheridan B, Taylor S, Wyatt P
Final Report of the Clinical Sub-Committee, Ontario Provincial Advisory
Committee on New Predictive Genetic Technologies, November 30, 2001
Committee members: Birtwhistle RV, Feldman W, Hunter A, Shugar A, Velsher L,
Viner G, Wells P
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Final Report of the Psychosocial Sub-Committee, Ontario Provincial Advisory
Committee on New Predictive Genetic Technologies, November 12, 2001Committee
members: Esplen MJ, Aronson M, Cappelli M, Hunter J, Lachance M, Liede A,
Robert F, Swayze A, Webb N
Final Report of the Education Sub-Committee, Ontario Provincial Advisory
Committee on New Predictive Genetic Technologies, November 27, 2001
Committee members: Blaine S, Carroll J, Balsys S, Bell M, Burfoot A, Byrne N,
Esplen MJ, Johnson I, Lachance M, Meschino W, Maddox G, Poudrier J
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Appendix F
The Toolkit – The Evaluation Template
Submitted by the Sub-Committee on Evaluation
Provincial Advisory Committee on New Predictive Genetic Technologies
Contents
Part 1 About the Evaluation Tool Kit
Part 2 Flowchart for using the Evaluation Template
Part 3 Evaluation Template
Part 4 The Summary Evaluation Template
Part 5 Application for Service Evaluation
Part 6 A Glossary of Terms
Part 1. About the Evaluation Tool Kit
The Evaluation Sub-Committee has developed a Tool Kit to assist the Advisory
Committee and the Expert Panels in their decision processes. The tool kit has five
components:
(Part 2.) Flowchart for using the Evaluation Template
This chart schematizes, in graphic form, the steps to be taken in the evaluation of a
proposed predictive genetic service
(Part 3.) The Evaluation Template
The Evaluation Template is an 11 page form which lists questions to be answered,
and decisions to be taken, in the evaluation of specific predictive genetic services.
The template has five sections, each of which outlines a specific criterion for
evaluation (intended purpose, effectiveness, additional effects, economic
considerations and expected demand & expansion potential). Most of these sections
have sub-categories of questions to be answered. Completion of the template requires
a review of available evidence, and committee deliberation. Both the Advisory
Committee and the Expert Panel will contribute to the completion of the Template.
(Part 4.) The Summary Evaluation Template
The Summary Evaluation Template is a one page form for the presentation of
summary information about each of the five main criteria assessed in the evaluation
of a predictive genetic service. This summary form can be completed by the
Advisory Committee once the full Evaluation Template is finished. It can be used by
decision-makers to quickly review the main findings of the Advisory Committee.
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(Part 5.) Application for Service Evaluation
This is a sample application form that lists the issues to be addressed by the
individual or group advocating for the public funding of a new predictive genetic
service. Completion of this form constitutes step one in the process for decision
making.
(Part 6.) A Glossary of Terms
The Glossary of Terms identifies a series of terms that are particular to the
evaluation template and of more generic relevance to genetic disorders and genetic
testing. This glossary should be of assistance to members of the Advisory Committee
and the Expert Panel, to ensure that there is common understanding of the main
terms and concepts being used in the evaluation.
These tools are for guidance only. In many cases, the evaluation will require
techniques that are more sophisticated than the tools supplied. We rely on Expert
Panels to use appropriate methodologies. We assume that with experience these
tools will evolve over time and become increasingly useful. 
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Part 2. Flowchart for Using the Evaluation Template
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Section 1. 
Intended Purpose of
Proposed Service
Step #1: Does the intended purpose of this service
justify continuing with the evaluation?
Section 2.
Effectiveness of
Proposed Service
Step #2: Does the performance of the test in the
laboratory justify further evaluation?
1.1 Introduction to
Proposed Service
1.2 Elements of
Proposed Service
1.3 Summary of
Intended Purpose
2.1 Analytical validity
Yes Grey Zone No
Yes Grey Zone No
Proceed with Evaluation
Proceed with Evaluation
Template Criteria to 
be Evaluated
Evaluation Steps
Conditions
May Apply
Reject 
Proposed 
Conditions
May Apply
Reject 
Proposed 
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Section 2.
Effectiveness of
Proposed Service
(cont’d)
Step #3: Does the clinical performance of the test
justify further evaluation?
Section 2.
Effectiveness of
Proposed Service
(cont’d)
Step #4: Considering the alternatives to the
proposed service (section 2.3) and the expected
outcomes of service use (section 2.4) does the
information justify proceeding with the evaluation?
2.2 Clinical Validity
2.3 Availability &
Effectiveness of
Alternatives
2.4 Expected outcomes
of Service Use
Yes Grey Zone No
Yes Grey Zone No
Proceed with Evaluation
Proceed with Evaluation
Template Criteria to 
be Evaluated
Evaluation Steps
Conditions
May Apply
Reject 
Proposed 
Conditions
May Apply
Reject 
Proposed 
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Section 3. 
Additional Effects of
Proposed Service
Step #5: Are the known and potential additional
effects of the proposed service acceptable?
Section 4 
Economic
Considerations for
Proposed Service
Step #6: Are the known and potential costs of
providing the proposed service acceptable?
4.1 Costs of proposed
service
4.2 Expected demand
4.3 Expansion potential
Yes Grey Zone No
Yes Grey Zone No
Proceed with Evaluation
Proceed with Evaluation
Template Criteria to 
be Evaluated
Evaluation Steps
Conditions
May Apply
Reject 
Proposed 
Conditions
May Apply
Reject 
Proposed 
Part 3. Evaluation Template
Section 1. Intended Purpose of Proposed Service:
1.1 Introduction to Proposed Test/Service
Description of the evaluation task
1.2 Elements of Proposed Service
1.2a. Clinical condition.
Specify the clinical condition for which the service is intended, including the
prevalence or incidence of the condition (and variation across populations), its
clinical manifestations and natural history, to the extent known. Describe the
genetic basis of the clinical condition, including mode of inheritance,
penetrance and expressivity (see glossary). 
1.2b. Test technology (ies).
Provide a description of the proposed test. Describe the specific laboratory
measurement(s) of the test, e.g. specific mutation, metabolite, enzyme activity.
The description should be written in a language that would be understandable
to non-laboratorians.
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1.2c Target population.
Specify the target population(s) for which the service is intended, e.g. members
of high-risk families, ethnic populations, clinically-defined high risk groups,
etc. Specify who will be eligible for testing, i.e. the criteria for test eligibility.
1.3 Summary of Intended Purpose
Summarize the intended purpose of the service.
The intended purpose of the service consists of a clear presentation of what it
is supposed to do and why it would make an important contribution to health
from the individual, familial or population perspective. If a test has multiple
potential purposes, each should be described separately.
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Step #1. Evaluation of Intended Purpose of Service;
Considering the above information, does the intended purpose of this service
justify continuing with the evaluation?
w No Recommend rejection of proposed service
w Yes Continue with evaluation
w “Grey Zone” Continue with evaluation; identify relevant
concerns and propose ways to resolve them:(Uncertain)
Section 2. Effectiveness of Proposed Service:
2.1 Analytic Validity (Test Performance)
2.1a. Analytical validity
Specify the analytical validity of the proposed test technology. Analytical validity
is defined as the extent to which a test measures or detects the analyte it is
intended to measure or detect. An analyte is defined as the substance measured
by a laboratory test, e.g. DNA mutation, allele, chromosome, metabolites or
enzyme activity. Analytical validity is expressed by sensitivity (the probability
that a test will detect an analyte when it is present in the sample), specificity (the
probability that a test will be negative when an analyte is absent from a sample)
and accuracy (the proportion of correct test results) under defined conditions. 
2.1b Qualifying statements
Outline potential concerns about the analytical validity of the proposed service,
or the quality of the available evidence about analytical validity. Outline any
concerns about the reliability of the test under normal (as distinct from
experimental) conditions.
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Step #2. Evaluation of Analytical Validity of Proposed Service;
Considering the above information (from 2.1a and 2.1b), does the
performance of the test in the laboratory justify further evaluation?
w No Recommend rejection of proposed service
w Yes Continue with evaluation
w “Grey Zone” Continue with evaluation; identify relevant
concerns and propose ways to resolve them:(Uncertain)
2.2 Test Performance (Clinical validity)
A predictive test makes claims about its performance in predicting the occurrence of
a future clinical state for an individual; in some cases it makes claims about the
expected severity of that state and or the time, or age, of expected onset.
Information from predictive tests for inherited conditions may also inform
predictions about future clinical states for family members of the tested person. 
For predictive tests relating to the measurement of gene mutations or their
products, the methods for assessing clinical validity will depend on the penetrance
of the mutation. For fully penetrant mutations, the presence or absence of the
mutation provides complete information about the probability of the future clinical
condition, and the validity of the test can be assessed using the diagnostic test
evaluation paradigm. Analytical test performance and clinical test performance are
closely related, though lab practices may reduce the reliability of test results.
For partially penetrant mutations, the absence of the mutation (a negative test)
may be informative in ruling out an increased risk of a particular condition. But, the
presence of a mutation (a positive test) confers only a probability for the
development of the clinical condition. This is usually expressed in terms of ‘risk’.
The absolute risk of developing the condition may be expressed as a simple
probability, or percentage for an individual and this may be age-related (e.g., given
the presence of mutation X, the risk of developing condition X1 is 40% by the age of
40 years). The risk can also be expressed relative to the underlying risk in the
population. For example, a mutation may confer a relative risk of 3.5, meaning that
the risk of developing the condition is 3.5 times that of the underlying population
from which the individual was selected or sampled.
The test’s performance is assessed according to sensitivity, specificity, accuracy
and predictive values and relies, to a greater or lesser degree, on the kind of clinical
population studied. The clinical validity of the test performance relates to the
adequacy of the data, the confidence with which claims about the test’s predictive
power can be made (including claims about predictive power for age at onset or
severity, where made), and the validity of the results in both the test populations,
and other (non-test) populations.
2.2a Test performance (clinical)
Specify the expected performance of the test under clinical conditions, and the
information it is expected to provide about future clinical conditions in tested
individuals.
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2.2b Validity of clinical test performance
Describe the best available evidence from which validity can be assessed, and
outline potential concerns about the claims for clinical validity of the proposed
service.
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Step #3. Evaluation of Clinical Validity of Proposed Service:
Considering the above information (from 2.2a and 2.2b), does the clinical
performance of the test justify further evaluation?
w No Recommend rejection of proposed service
w Yes Continue with evaluation
w “Grey Zone” More Information Required 
If clinical validity is not completely established,
specify ways in which additional data could be
gathered that might help confirm the clinical
validity, e.g. pilot testing in selected groups
A pilot or a full study may be justified to obtain 
the necessary information
w “Grey Zone” Orphan Disease 
In the case of orphan diseases where clinical 
validity is suggested but not completely 
established, specify how the proposed service
should be used in clinical practice 
Standardized protocols and circumstances for clinical
practice could be developed by other sub-committees
(Uncertain)
(Uncertain)
2.3 Availability and Effectiveness of Alternatives to Proposed Service
2.3a. Alternatives to proposed testing service
Discuss the availability and effectiveness of other a) laboratory methods or b)
ways to estimate risk or genetic status for the same or similar predictive
purposes. 
2.3b. Alternative sources of risk information
What additional clinically useful information is being provided that makes the
proposed service test more useful than the alternatives?
Is the proposed service intended to a) complement or b) replace one or
more of these other methods? Please explain.
2.4 Expected Outcomes of Service Use
2.4a. Medical interventions
Discuss the extent to which knowledge of genetic risk status can alter the
approach to the overall management of the clinical condition (i.e. what other
factors, such as environment, lifestyle, or other medical conditions, may
influence the development or prognosis of this condition, irrespective of test
results). 
Discuss the availability and effectiveness of clinical interventions to reduce
the problems associated with the condition, e.g. clinical treatments,
surveillance protocols. 
Also, identify potential negative clinical outcomes for tested person arising
from use of the service, e.g., the use of potentially dangerous treatment or
surveillance options, the risk of false positive or negative results and the
consequences of inconclusive test results.
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2.4b Non-medical interventions
Discuss the availability and significance of non-medical interventions to aid
tested persons or family members, including the usefulness of the information to
diagnosed persons for personal and family planning, uncertainty reduction, etc. 
Also, identify potential negative outcomes for tested persons arising from
use of the service, e.g. reduced insurability, increased fatalism, residual
uncertainty from inconclusive results, etc.
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Step #4. Evaluation of Alternatives to Proposed Service and Outcomes 
of Proposed Service:
Considering the alternatives to the proposed service (section 2.3) and the
expected outcomes of service use (section 2.4), does the information justify
proceeding with the evaluation?
w No Recommend rejection of proposed service
w Yes Continue with evaluation
w “Grey Zone” Continue with evaluation; identify relevant
concerns and propose ways to resolve them:(Uncertain)
Section 3. Additional Effects of Proposed Service
3.1 Additional Effects
n Identify the additional effects of the proposed service, both known and
potential. Additional effects are those effects that extend beyond expected or
intended outcomes for the tested individual to individuals other than the
person tested, including the family and the community.
Examples of additional effects include:
n discovery of non-paternity
n detracting from a family member’s right not to know their diagnosis
n learning the risk status of a minor,
n gender effects
n potential for discrimination
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Step #5. Evaluation of Additional Effects of Proposed Service
Considering the above information (from section 3.1), are the known and
potential additional effects of the proposed service acceptable?
w No Recommend rejection of proposed service
w Yes Continue with evaluation
w “Grey Zone” Limitations on Clinical Practice 
Specify limitations on clinical practice
Standardized protocols and circumstances for 
clinical practice could be developed by other 
sub-committees
w “Grey Zone” More information required 
Specify ways in which additional data could be
gathered that might help in the evaluation of the
additional effects of the proposed service 
A pilot or a full study may be justified to obtain the
necessary information
(Uncertain)
(Uncertain)
Section 4. Economic Considerations 
4.1 Costs of Proposed Service
Discuss the available data on the direct costs of the proposed service. These
considerations may include:
n the laboratory testing algorithm
n the personnel providing all components of the service
n the equipment and overhead expenses
4.2 Expected Demand for Proposed Service
What is the anticipated demand for the proposed service in the target
population? The expected demand reflects the quantity of services that would
be provided if the service were covered.
Discuss the factors that are likely to affect the demand for the proposed
service. Provide some indication of the confidence the committee has in these
estimates.
Provide an estimate of the expected demand for the proposed service
w High
w Low
w Moderate
w Uncertain
4.3 Expansion Potential for Proposed Service
4.3a Expansion potential
What is the potential for expansion of the proposed service? Expansion
potential is the likelihood that the genetic testing service, once covered, may
become redefined in the course of clinical practice or product marketing to
include broader populations, clinical contexts or indications. This will be
determined not only by the prevalence of associate diseases, but also by
popular beliefs about the relevance of information about risk status, and the
availability of product marketing.
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Discuss the factors that are likely to affect the expansion potential of the
proposed service. Provide some indication of the confidence the committee has
in these estimates.
Provide an estimate of the expansion potential of the proposed service.
w High
w Low
w Moderate
w Uncertain
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Step #6. Consideration of The Economic Impact of The Proposed Service: 
A formal economic evaluation is not required. Please refer to background
document 7.3.
Considering the above information (from section 4), are the known and
potential costs (immediate costs and demands) of providing the service
affordable?
w No Recommend rejection of proposed service
w Yes Proceed with evaluation
w “Grey Zone” Limitations 
Specify limitations on clinical practice or identify 
a time line for re-evaluation
Periodic re-evaluation processes, research protocols
and clinical protocols could be developed
(Uncertain)
Part 4. Evaluation Template: Summary
1. Intended Purpose of Service
n Intended Purpose of the Proposed Service (from Section 1):
n Recommendations (from 1.3, Step #1)
2. Effectiveness of Proposed Service
n Recommendations (from Section 2, Steps #2 through #4)
3. Additional Effects of Proposed Service
n Recommendations (from Section 3, Step #5)
4. Economic Considerations
n Recommendations (from section 4, Step #6)
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Part 5: Application for Service Evaluation
Applicant Information 
Contact Name:
Organization:
Address:
Phone: Fax: Date:
Application Form
1. Clinical Condition.
Specify the clinical condition for which the service is intended, including the
prevalence or incidence of the condition (and variation across populations), its
clinical manifestations and natural history, to the extent known. Describe the genetic
basis of the clinical condition, including mode of inheritance, penetrance and
expressivity (see glossary). 
2. Test Technology (ies).
Provide a description of the proposed test. Describe the specific laboratory
measurements(s) of the test, e.g. specific mutation, metabolite, enzyme activity. The
description should be written in a language that would be understandable to non-
laboratorians.
3. Target Population.
Specify the target population(s) for which the service is intended, e.g. members of
high-risk families, ethnic populations, clinically-defined high-risk groups, etc.
Specify who will be eligible for testing, i.e., the criteria for test eligibility.
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4. Expected Demand for Proposed Service
What is the anticipated demand for the proposed service in the target population?
The expected demand reflects the quantity of services that would be provided if the
service were covered.
5. Alternatives to Proposed Service
Discuss the availability and effectiveness of other a) laboratory methods or b) ways
to estimate risk or genetic status for the same or similar predictive purposes. What
additional clinically useful information is being provided that makes the proposed
service test more useful than the alternatives?
Is the proposed service intended to a) complement or b) replace one or more of
these other methods?
6. Effectiveness of Proposed Service:
a) Analytic validity
Analytical validity is defined as the extent to which a test measures or detects
the analyte it is intended to measure or detect. An analyte is defined as the
substance measured by a laboratory test, e.g. DNA mutation, allele,
chromosome, metabolites or enzyme activity. Analytical validity is expressed by
sensitivity (the probability that a test will detect an analyte when it is present
in the sample), specificity (the probability that a test will be negative when an
analyte is absent from a sample) and accuracy (the proportion of correct test
results) under defined conditions.
Specify the analytical validity of the proposed test technology. Outline
potential concerns about the analytical validity of the proposed service, or the
quality of the available evidence about analytical validity. Outline any concerns
about the reliability of the test under normal (as distinct from experimental)
conditions
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b) Clinical validity
A predictive test makes claims about its performance in predicting the
occurrence of a future clinical state for an individual; in some cases it makes
claims about the expected severity of that state and or the time, or age, of
expected onset. Information from predictive tests for inherited conditions may
also inform predictions about future clinical states for family members of the
tested person. 
For predictive tests relating to the measurement of gene mutations or their
products, the methods for assessing clinical validity will depend on the
penetrance of the mutation. For fully penetrant mutations, the presence or
absence of the mutation provides complete information about the probability
of the future clinical condition, and the validity of the test can be assessed
using the diagnostic test evaluation paradigm. Analytical test performance and
clinical test performance are closely related, though lab practices may reduce
the reliability of test results.
For partially penetrant mutations, the absence of the mutation (a negative
test) may be informative in ruling out an increased risk of a particular
condition. But, the presence of a mutation (a positive test) confers only a
probability for the development of the clinical condition. This is usually
expressed in terms of risk. The absolute risk of developing the condition may
be expressed as a simple probability, or percentage for an individual and this
may be age-related (e.g., given the presence of mutation X, the risk of
developing condition X1 is 40% by the age of 40 years). The risk can also be
expressed relative to the underlying risk in the population. For example, a
mutation may confer a relative risk of 3.5, meaning that the risk of developing
the condition is 3.5 times that of the underlying population from which the
individual was selected or sampled.
The test’s performance is assessed according to sensitivity, specificity,
accuracy and predictive values and relies, to a greater or lesser degree, on the
kind of clinical population studied. The clinical validity of the test performance
relates to the adequacy of the data, the confidence with which claims about the
test’s predictive power can be made (including claims about predictive power
for age at onset or severity, where made), and the validity of the results in both
the test populations, and other (non-test) populations.
Specify the expected performance of the test under clinical conditions, and
the information it is expected to provide about future clinical conditions in
tested individuals.
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7. Summary 
Summarize the intended purpose of the service.
The intended purpose of the service consists of a clear presentation of what it is
supposed to do and why it would make an important contribution to health from
the individual, familial or population perspective. If a test has multiple potential
purposes, each should be described separately.
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Part 6. Glossary of Terms
Glossary of Terms for the Evaluation Template
Additional effects
Additional effects are those effects that extend beyond expected or intended
outcomes for the tested individual, to individuals other than the tested
individual. These effects include effects on family, and community, e.g.
discovery of non-paternity, detracting from a family member’s right not to
know their diagnosis, learning the risk status of a minor, gender effects,
potential for increased discrimination, etc.
**Analytical validity
Analytical validity is defined as the extent to which a test measures or detects
the analyte it is intended to measure or detect. An analyte is defined as the
substance measured by a laboratory test, e.g. DNA mutation, allele,
chromosome, metabolites or enzyme activity. Analytical validity is expressed by
sensitivity (the probability that a test will detect an analyte when it is present
in the sample), specificity (the probability that a test will be negative when an
analyte is absent from a sample) and accuracy (the proportion of correct test
results) under defined conditions.
**Clinical validity
Clinical validity is defined as the accuracy with which a laboratory
measurement predicts the presence or absence of a clinical condition.
A predictive test makes claims about its performance in predicting the
occurrence of a future clinical state for an individual; in some cases it makes
claims about the expected severity of that state and or the time, or age, of
expected onset. Information from predictive tests for inherited conditions may
also inform predictions about future clinical states for family members of the
tested person. 
For predictive tests relating to the measurement of gene mutations or their
products, the methods for assessing clinical validity will depend on the
penetrance of the mutation. For fully penetrant mutations, the presence or
absence of the mutation provides complete information about the probability
of the future clinical condition, and the validity of the test can be assessed
using the diagnostic test evaluation paradigm. In this case, the test’s
performance is assessed according to sensitivity, specificity, accuracy and
predictive values. 
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For partially penetrant mutations, the absence of the mutation (a negative
test) may be informative in ruling out an increased risk of a particular
condition. But, the presence of a mutation (a positive test) confers only a
probability for the development of the clinical condition. This is usually
expressed in terms of risk. The absolute risk of developing the condition may
be expressed as a simple probability, or percentage for an individual and this
may be age-related (e.g., given the presence of mutation X, the risk of
developing condition X1 is 40% by the age of 40 years). 
The risk can also be expressed relative to the underlying risk in the
population. For example, a mutation may confer a relative risk of 3.5, meaning
that the risk of developing the condition is 3.5 times that of the underlying
population from which the individual was selected or sampled.
Service
The unit of analysis for the evaluation framework is the genetic test service,
which we define as the package of: test technology + target population +
clinical condition. The intended purpose of the service consists of a clear
argument regarding what it is supposed to do and why it would make an
important contribution to the health of the population. The purpose must
apply to the fully defined service.
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